Inhibition of HIF prolyl 4-hydroxylases protect endothelial cells from apoptosis by Dimitrova, Tatyana Stefanova
T
A
T
Y
A
N
A
 
S
.
 
D
I
M
I
T
R
O
V
A
 
 
 
 
P
R
O
T
E
C
T
I
O
N
 
O
F
 
E
C
S
 
F
R
O
M
 
A
P
O
P
T
O
S
I
S
9 7 8 3 8 3 5 9 5 6 2 5 4
VVB LAUFERSWEILER VERLAG
STAUFENBERGRING 15
D-35396 GIESSEN
Tel: 0641-5599888 Fax: -5599890
redaktion@doktorverlag.de
www.doktorverlag.de
VVB LAUFERSWEILER VERLAG
édition scientifique
VVB
Tatyana Stefanova Dimitrova
Inhibition of HIF prolyl 4-hydroxylases 
protect endothelial cells from apoptosis
 INAUGURAL DISSERTATION submitted to the Faculty of Medicine 
in partial fulfillment of the requirements for the PhD-Degree 
of the Faculty of Medicine of the Justus-Liebig-University Giessen 
VVB LAUFERSWEILER VERLAG
édition scientifique
ISBN: 978-3-8359-5625-4
Das Werk ist in allen seinen Teilen urheberrechtlich geschützt. 
Jede Verwertung ist ohne schriftliche Zustimmung des Autors 
oder des Verlages unzulässig. Das gilt insbesondere für 
Vervielfältigungen, Übersetzungen, Mikroverfilmungen
 und die Einspeicherung in und Verarbeitung durch 
elektronische Systeme.
1. Auflage 2010
All rights reserved. No part of this publication may be
 reproduced, stored in a retrieval system, or transmitted, 
in any form or by any means, electronic, mechanical, 
photocopying, recording, or otherwise, without the prior 
written permission of the Author or the Publishers.
st1  Edition 2010
©  2010 by VVB LAUFERSWEILER VERLAG, Giessen
Printed in Germany 
VVB LAUFERSWEILER VERLAG
STAUFENBERGRING 15, D-35396 GIESSEN
Tel: 0641-5599888 Fax: 0641-5599890 
email: redaktion@doktorverlag.de
www.doktorverlag.de
édition  scientifique
 
 
 
 
 
Inhibition of HIF prolyl 4-hydroxylases  
protect endothelial cells from apoptosis 
 
 
 
 
 
INAUGURAL DISSERTATION  
submitted to the Faculty of Medicine  
in partial fulfillment of the requirements  
for the PhD-Degree  
of the Faculty of Medicine  
of the Justus-Liebig-University Giessen  
 
 
 
 
by 
 
 
Tatyana Stefanova Dimitrova 
of 
Silistra, BULGARIA 
 
 
 
 
Giessen (2010) 
 
  
 
From the Department of Physiology  
Director/Chairman: Prof. Dr. K. D. Schlüter 
of the Faculty of Medicine of the Justus-Liebig-University Giessen  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
First Supervisor:       PD. Dr. Thomas Noll 
Second Supervisor:       Prof. Dr. Hugo Marti (Heidelberg) 
Committee Members:      Prof. Dr. Martin Diener 
             Prof. Dr. Lienhard Schmitz 
 
 
 
 
 
 
Date of Doctoral Defense:     01.10.2010 
 
 
 
 
 
 
 
 
 
 
                     
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                     
           Logical thinking is the example of a complete fiction 
                   Friedrich Nietzsche 
 
 
 
 
 
 
. 
4 
 
TABLE OF CONTENTS 
 
Abbreviations                          6 
1 INTRODUCTION                       10 
Background                          10 
1.1    Ischemia/reperfusion injury                 10 
1.2    Endothelial cell changes related to ischemia/reperfusion       11 
1.3      Cell death during ischemia/reperfusion            12 
1.4      Protective strategies against ischemia/reperfusion        13 
1.4.1   Preconditioning                     13 
1.4.2   Postconditioning                      14 
1.4.3   Pharmacological postconditioning                15 
1.5      Role of HIF-1α in cell survival during ischemia/reperfusion injury   15 
1.5.1   Regulation of HIF                    16 
1.5.2   Alternative modifications affecting HIF-1α transcription      18 
1.5.3   Pharmacological manipulation of HIF-1α            18 
1.6    Alternative regulators                   20 
1.6.1   Regulation of p53                    20 
1.6.2   HIF-1α-p53-interplay                   21 
1.7    Mdm2                        22 
1.7.1   Regulation of Mdm2                   22 
1.8      HIF-1α and Mdm2 interplay                23 
1.9      Working hypothesis                   24 
1.10   Aims of the study                    26 
2 MATERIALS                        27 
2.1   Chemicals and consumables                 27 
2.2   siRNAs                        30 
2.3    Antibodies                       31 
2.4    Laboratory equipment                  32 
3 METHODS                         33 
3.1    Isolation and cultivation of human umbilical vein endothelial cells   33 
3.2    Subcultivation of endothelial cells              34 
3.3    Experimental protocol for hypoxia/reoxygenation         34 
3.4    siRNA interference                    36 
3.5    SDS polyacrylamide gel electrophoresis (SDS-PAGE)       36 
3.6    Western blot                       38 
3.6.1   Stripping membranes                   39 
3.7    Immunoprecipitation                   40 
3.8    Nuclear and cytoplasmic protein extraction           41 
3.9    Determination of protein concentration by Bradford         42 
3.10    FACS analysis                     42 
3.11   Immunoflorescence                   42 
3.12    Statistical analysis                    43 
5 
 
4 RESULTS                          44 
4.1 Effect of DMOG on endothelial apoptosis during reoxygenation   44 
4.2   Effect of DMOG on HIF-1α content during reoxygenation in  
endothelial cells                    45 
4.3    Effect of DMOG on p53 protein content during reoxygenation    48 
4.4    Effect of PHD2 silencing on HIF-1α and p53 content in  
serum starvation-induced apoptosis during reoxygenation        50 
4.5    Effect of HIF-1α silencing on p53 protein levels and  
serum starvation-induced apoptosis during reoxygenation     51 
4.6    Effect of pharmacological inhibition of p53 on serum  
starvation-induced apoptosis during reoxygenation        53 
4.7   Effect of DMOG on HIF-1α and p53 localization         54 
4.8   Interaction between HIF-1α and p53             55 
4.9    Effect of PHD inhibition by DMOG on Mdm2 and p53       56 
4.10    Interaction between HIF-1α and Mdm2            57 
4.11    Effect of Mdm2 silencing on p53 and analysis of Mdm2 and  
    interaction for subsequent p53 degradation           58 
4.12   Effect of Mdm2 silencing on DMOG-induced cell survival      60 
5 DISCUSSION                        61 
5.1   Main findings                      61 
5.2    Inhibition of PHD protects endothelial cells from ongoing apoptosis  61 
5.3    Inhibition of PHD affects pro-apoptotic p53           62 
5.4    p53 downregulation is dependent of HIF-1α stabilization      64 
5.5    Stabilization of HIF-1α regulates Mdm2, specific E3-ubiquitin  
     ligase responsible for limiting the levels of p53         65 
5.6    HIF-1α induced p53 degradation is mediated via Mdm2      66 
6 SUMMARY                         69 
7 ZUSAMMENFASSUNG                    71 
8 REFERENCES                        73 
9 ACKNOWLEDGEMENTS                   82 
10 CURRICULUM VITAE                    83 
11 PUBLISHED ABSTRACTS                 84 
12 PUBLICATION                      85 
13 ERKLÄRUNG                        86 
6 
 
ABBREVIATIONS 
 
AA Acrylamid 
ANOVA   Analysis of variance 
APAF-1  Apoptotic Protease Activating Factor-1 
APS  Ammonium per sulfate 
ARF              Alternate reading frame 
ATP               Adenosin Tri-Phosphat  
ATR              The ataxia telangiectasia rad-3-related kinase 
Bax               Bcl-associated X protein 
Bcl-2              B-cell lymphoma gene 2 
Bcl-xL              Lange Spleissvariante des Bcl-x Proteins 
BisAA   Bisacrylamid 
BSA   Bovine serum albumin 
°C  Degree celcius  
CaCl2   Calcium chloride 
CBP cAMP           Response element-binding protein  
CBP/p300 Interacting transactivator  
CO2  Carbon dioxide 
Ctr   Control 
ddH2O Double-distilled water  
DMOG   Dimethyloxalyl glycine 
DMSO      Dimethyl sulfoxide 
DNA     Deoxyribonucleic acid  
DTT    Dithiothreitol 
EC Endothelial cells 
ECGS Endothelial cell growth supplement 
ECL Enhanced chemiluminescence 
EDTA Ethylene diamine tetraacetic acid 
e.g For example 
EGTA  Ethylene glycol-bis(2-aminoethylether)N,N,N',N' 
7 
 
EPO              Erythropoietin 
FACS  Fluorescence activated cell sorter 
FCS Fetal calf serum 
FITC  Fluorescein-5-isothiocyanat 
FIH  Factor-inhibiting HIF-1 
h                Hours 
H           Hypoxia 
H2O       Water 
HBSS           Hank's balanced salt solution 
HCl  Hydrochloric acid  
hEGF     Human epidermal growth factor 
HEPES     4(2-hydroxyethyl)1piperazine ethane sulfon 
HIF-1α          Hypoxia-inducible faktor alpha 
HLH          Helix-Loop-Helix  
HO-1             Heme Oxygenase-1 
H/R Hypoxia/reperfusion 
HRE          Hypoxia responsive elements  
HRP             Horseradishperoxidase 
HSP90 Heat shock protein 90 
HUVEC Human umbilical vein endothelial cells 
IgG           Immunglobulin G 
IL-8              Interleukin 8 
iNOS             Inducible nitric oxide synthase 
IP         Immunoprecipitation  
I/R         Ischemia/reperfusion 
IU          International unit 
KCl          Potassium chloride 
kDa           Kilo Dalton 
KH2PO4         Potassium dihydrogen phosphate 
M             Molar 
mM Millimolar 
8 
 
µM Micromolar 
Mdm2           Mouse doubles minute 2 
MgCl2         Magnesium chloride 
MG-132 Proteasome inhibitor 
min         Minutes 
N          Normoxia 
NaCl       Sodium chloride 
NaF          Sodium fluoride 
Na2HPO4    Di-sodium hydrogen phosphate 
NES Nuclear export signals 
NLS Nuclear localization signal 
nM Nanomolar 
NO               Nitric oxyde  
NP-40     Nonidet P-40 
NS Nonsense 
O2        Oxygen 
ODD         Oxygen-dependent degradation domain 
OH        Hydroxyl 
p53         Tumor suppressor protein 53 kDa  
PAGE       Polyacrylamid-Gelelektrophorese 
PAR-2              Protease activated receptor-2 agonist 
PBS       Phosphate buffered saline 
PFT-α         Pifithrin alpha 
PFA               Paraformaldehyd 
PHD          Prolyl hydroxylase domain protein 
pH          Negative log of H+ concentration 
PI         Propidium-Jodid  
PMSF           Phenylmethylsulfonyl fluoride 
Po2   Oxygen partial pressure 
RISK             Reperfusion injury survival kinases  
RNA     Ribonucleic acid 
9 
 
siRNA         RNA interference 
ROS           Reactive oxygen species 
RT         Room temperature 
s        Second 
SD          Standard deviation 
SDS    Sodium dodecyl sulfate 
TBS      Tris-buffered saline 
TEMED         N, N, N’, N’,-tetramethylethylenediamine 
TOPRO-3            Stain 
Tris        Tris(hydroxymethyl)aminomethane 
Tween 20           Polyoxyethylene-sorbitan-monolaureate 
U/ml     Units/ml 
VHL        von Hippel-Lindau 
WB           Western blot 
% vol/vol         Volume by volume percentage 
% wt/vol          Weight by volume percentage 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
10 
 
1 INTRODUCTION 
Background  
Hypoxia/reoxygenaion (H/R) is one of the most frequent complications leading to 
necrotic or apoptotic cell-death in the heart as well as in other organs. Since H/R is 
normally an unpredictable event, a strategy like preconditioning is of limited clinical 
relevance in protecting the heart against reperfusion-induced injury. Therefore, a 
maneuver like postconditioning, aiming to protect the heart at the onset or during 
reperfusion has gained much greater clinical interest. In this context, the hypoxia-
inducible factor (HIF-1α) has emerged into focus. It is well established that HIF-1α is 
stabilized under hypoxic conditions and involved in transcriptional and non-
transcriptional regulation of key pathways for hypoxic adaptation of cell metabolism and 
cell survival. With the onset of reoxygenation, however, HIF-1α is rapidly degraded and 
its effect on hypoxic adaptation is ebbing. HIF-1α stability is controlled by HIF-1α prolyl 
4-hydroxylase-2 (PHD2), targeting HIF-1α for degradation in presence of oxygen. The 
central hypothesis of the present study is that preservation of HIF-1α beyond the period 
of hypoxia may enhance the protective effect of HIF-1α on endothelial cells against 
ongoing apoptotic cell death during H/R. 
1.1 Ischemia/reperfusion injury  
The cardiovascular system supplies the tissues of the body with blood. Restriction of 
regional blood flow results in ischemia, which causes the cellular oxygen tension to 
decrease and the carbon dioxide tension to rise. Clinically, the treatment for ischemia 
involves reestablishing blood flow to the ischemic tissue. However, reperfusion of 
ischemic tissue paradoxically triggers the morphological appearance of tissue injury, 
presumably by initiating events that contribute to the activation of cell-death pathways. 
The cellular events leading to ischemia/reperfusion (I/R) -induced cellular injury are 
complex, but the key elements include radical production, cellular disturbances of 
calcium homeostasis, and activation of cellular proteases. This has led to the concept of 
I/R injury as a sequence of events that contribute to cell death (Braunwald and Kloner 
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1985). It has been observed that different cell types show widely differing sensitivity to 
I/R. 
1.2 Endothelial cell changes related to ischemia/reperfusion 
Endothelium is the first line of defense between the circulation and the vessel wall. The 
integrity of endothelium is necessary for the function of the whole cardiovascular system. 
Vascular endothelium, when unperturbed, provides a surface to the blood vessel, and 
has the potential to regulate the passage of materials and the transit of blood cells in 
and out of the bloodstream. This characteristic is essential for vascular homeostasis. 
Endothelial cells are important in modulating the pathophysiology of I/R injury. It is 
known to cause changes in endothelial cells, including membrane depolarization, 
increased membrane fluidity, perturbations in the distribution of ions, cell swelling, 
cytoskeletal derangements, and recruitment and activation of inflammatory cells 
(Menger and Vollmar, 2007). Many changes occur during reperfusion. The importance of 
apoptosis in cell death following ischemia and reperfusion has been demonstrated in in 
vivo rodent models. Gottlieb and coworkers (1994) reported that apoptosis occurs in the 
rabbit myocardium after 30 min of ischemia and 4 h of reperfusion, but not in the 
permanent ischemic period. Anversa and coworkers (1998) quantified the level of 
apoptosis and necrosis in the myocardium, and reported much higher levels of apoptosis 
after 2 h of ongoing ischemia. Cell death based on apoptosis was 86% versus 14% on 
necrosis. Until today, there are controversial data over the extent of the apoptosis 
following ischemia and reperfusion. Necrosis and apoptosis appear to be ongoing during 
ischemia, while apoptosis is boosted by the reperfusion event (Eefting et al., 2004). 
Increasing evidence suggests that apoptosis of endothelial cells can be responsible for 
endothelial dysfunction (Werner et al., 2006). In the very early stages of reperfusion, 
apoptosis is first seen in the endothelial cells from small coronary vessels (Lee et al., 
2005; Scarabelli T et al., 2001). The spread of apoptosis to surrounding cardiac 
myocytes suggests that reperfusion induces the release of soluble pro-apoptotic 
mediators from endothelial cells that promote cardiac myocyte apoptosis. The authors 
suggested that the spread of apoptosis to surrounding cardiac myocytes is due to 
reperfusion-induced release of soluble pro-apoptotic mediators from endothelial cells 
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that promote myocyte apoptosis. However, reperfusion also restores energy required for 
the completion of apoptosis and can accelerate the apoptotic process. It is well 
documented that, compared to other cells of the cardiovascular system, endothelial cells 
are metabolically robust and able to maintain a high phosphorylation potential 
(ATP/ADP) even under low oxygen content (Mertens et al., 1990). This metabolic 
robustness, however, makes endothelial cells rather prone to apoptotic stimuli that are 
generated during I/R by all type of myocardial cells (Lelli et al., 1998). In contrast to 
necrosis, which occurs in the absence of ATP, apoptosis is an energy dependent 
process. 
1.3 Cell death during ischemia/reperfusion  
Apoptotic cascade is regulated by a family of proteins called caspases. These apoptosis 
executor proteins are present as proforms in all cells. After cleavage, pro-caspases 
become active and initiate pathways leading to apoptosis. The signalling pathway 
leading to programmed cell death is fine-tuned by positive and negative regulators, and 
a tight balance between these factors decides whether the cell undergoes apoptosis or 
survives. Normally, the tumor suppressor p53 controls cellular homeostasis by affecting 
cell cycle progression and apoptosis. p53 induces apoptosis via transcriptional activation 
of pro-apoptotic genes or repression of anti-apoptotic genes. Alternatively, p53 may 
provoke transcriptional independent alterations in facilitating apoptosis by affecting the 
mitochondrial pathway of cell demise (Schmid et al., 2004; Caelles et al., 1994). p53 
regulates the expression of genes involved in growth arrest  (e.g p21Cip/WAF-1, 14-3-3G) 
and apoptosis (Puma, Bax, APAF-1), (Vousden and Lu 2002). Proteins that can shift the 
balance towards survival are the anti-apoptotic Bcl-2 and Bcl-xL, whereas the pro-
apoptotic proteins Bax, Bad, Bak, and Bid induce programmed cell death. p53 has been 
shown to accumulate under hypoxia and is clearly involved in the pathological response 
within endothelial cells (Stempien-Otero et al., 1999). Mechanisms, which are induced 
by ischemia or triggered by I/R leading to apoptotic cell death are still not fully 
understood. Endothelial cell death may contribute to hypoxia as well as the reperfusion 
components of this injury and different routes of protection need to be considered for the 
pre-ischemic or post-ischemic period.  
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Currently, there is no treatment for the heart tissue that directly aims to preserve the 
heart muscle during the time of blood deprivation and protect against reperfusion injury. 
Protecting the heart from I/R-induced injury represents the greatest challenge of 
cardiology, since myocardial infarction is the major cause of mortality in industrialized 
countries. 
1.4 Protective strategies against ischemia/reperfusion  
1.4.1 Preconditioning 
The known mechanisms of protection include targets in specific intracellular signalling 
pathways, functions of intracellular organelles such as sarcoplasmic reticulum, and 
mitochondria, and control of intracellular ion homeostasis. Other strategies for 
cytoprotection by activation of endogenous mechanisms occur in 2 mechanistically 
distinct phases: before or after the ischemic event occurs (Das et al., 2008). Firstly, 
ischemic preconditioning is the most successful form of pre-treatment to stimulate 
adaptive mechanisms in myocardium before the major ischemic event. The effects of the 
so called ‘first window’ or early preconditioning, lasts 1–2 h, after which the protection 
wanes. The so called ‘second window’ or late preconditioning occurs 24 h following the 
initial preconditioning ischemia and lasts for 48–72 h. A major distinction between the 
two stages is that early preconditioning has been shown to result in the modification of 
existing myocardial proteins, whereas late preconditioning is exerted by newly 
synthesized cytoprotective proteins in the heart (Downey et al., 2007). Following the 
initial discovery of preconditioning, it became clear that pharmacological agents could 
also exhibit cardioprotection when administered prior to the onset of sustained 
myocardial ischemia (Bolli et al., 2001). This is significant, since pharmacological agents 
could be more readily applied to clinical practice as a means of protecting the heart and 
other organs against I/R injury rather than to place ischemia directly. In ischemia, the 
best protection is achieved when these agents are administrated prior to ischemia, as in 
preconditioning (Pasupathy and Homer-Vanniasinkam, 2005). Аn alternative treatment 
opportunity to intervene at reperfusion is primary percutaneous coronary intervention 
and thrombolytic therapy. Apart from cardiac surgery, however, pre-ischemic treatment 
14 
 
of the myocardium is clinically of limited relevance, since acute myocardial infarction is 
normally an unforeseen event. Therefore, a maneuver like postconditioning, aiming to 
protect the heart at the onset or during reperfusion has gained much greater clinical 
interest (Vinten-Johansen et al., 2007). In reperfusion, the first seconds to minutes have 
the most significant impact on ‘acute’ reperfusion injury. In view of the acute changes 
during reoxygenation, protective interventions must be applied early on. Identification of 
such endogenous endothelial strategies may open new opportunities to protect 
endothelial cells from cell death. Еndothelial survival mechanisms which may also be 
activated under the same conditions are largely unknown.  
1.4.2 Postconditioning 
The postconditioning, consists of repeated brief episodes of ischemia and reperfusion 
(paralleling the durations used in preconditioning) (Zhao et al., 2003). By several cycles 
of postconditioning repeated at the onset of reperfusion, infarct size is reported to be 
reduced by up to 50% in canines. In addition, postconditioning reduced reperfusion 
arrhythmias (Halkos et al., 2004; Galagudza et al., 2004; Kloner et al., 2006), neutrophil 
adherence to the post-ischemic coronary artery, neutrophil accumulation in the area at 
risk, myocardial and endothelial injury (Zhao et al., 2003). The mechanisms responsible 
for the postconditioning-induced cardioprotection include endogenous stimulation of 
adenosine receptors, activation of the so called reperfusion injury survival kinases 
(RISK) (Hausenloy and Yellon 2007), opening of K ATP channels, attenuation of 
intracellular and mitochondrial calcium accumulation as well as inhibition of 
mitochondrial permeability transition pore opening (Zhao and Vinten-Johansen, 2006). 
One physiological mechanism by which postconditioning exerts its protective effects is 
by delaying the normalization of tissue pH in the heart during early reperfusion (Vinten-
Johansen et al., 2007). Studies have also revealed that postconditioning in vitro reduced  
reactive oxygen species (ROS) generation, which was also associated with reduced cell 
death (Sun et al., 2005). 
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1.4.3 Pharmacological postconditioning   
Studies have identified certain drugs, which reduce reperfusion injury, when given at 
reperfusion or reoxygenation. This approach is termed as ‘pharmacological 
postconditioning’ and has the advantage that they also can be used after myocardial 
infarction as well as in the situations of non-scheduled  infarct. Agents such as 
inhalational anaesthetics (Feng et al., 2005; Weber et al., 2005), bradykinin, the 
chemotherapeutic agents cyclosporine A (Lim et al., 2007), erythropoietin (EPO), nitric 
oxide (NO) (Johnson et al., 1991), hydrogen sulfide, and adenosine (Lefer et al., 2007) 
have demonstrated cardioprotective effects when given at reperfusion in experimental 
studies. Adenosine infusion at the onset of reperfusion has demonstrated 
cardioprotective effects in part by attenuating neutrophil–endothelium interactions. EPO, 
inhalational anaesthetics, bradykinin, and other agents activate RISK pathway. Another 
strategy used by Jiang and coworkers (2007) to enhance the effect of postconditioning is 
concomitantly delivered pharmacological agents. For instance the combination of 
postconditioning and a protease activated receptor-2 agonist (PAR-2), both applied at 
the onset of reperfusion, reduced infarct size to a greater range than either intervention 
alone (Jiang et al., 2007). Therefore, pharmacological agents may not only perform 
postconditioning, but they can also enhance its effects by triggering different pathways, 
extending its effects beyond the early reperfusion phase. 
1.5 Role of HIF-1α in cell survival during ischemia/reperfusion injury 
Over the past decade, HIF-1α has emerged as a key regulator of the molecular hypoxic 
response by mediating a wide range of physiological and cellular mechanisms 
necessary to adapt to oxygen deficiency. It has been reported that an increase in the 
level of HIF-1α is one of the first adaptive responses, at the molecular level, of 
myocardium to ischemia (Lee et al., 2000). Recent research (Eckle et al., 2008) has 
demonstrated that HIF-1α stabilization is central to cardio protection achieved through 
ischemic preconditioning. Moreover, Zhao and coworkers (2009) showed that 
cardioprotection by postconditioning is associated with up-regulation of HIF-1α 
expression. Furthermore, expression of a constitutively active HIF-1α hybrid has been 
shown to protect cardiac myocytes against I/R injury (Date et al., 2005). In this context, 
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increasing evidence suggests that cell survival during I/R can be influenced by the 
expression of genes that promote glycolysis, suppress ROS production, limit 
mitochondrial metabolism, and inhibit pro-apoptotic protein expression (Loor and 
Schumacker, 2008). HIF-1α is a member of transcription factors that regulate the 
expression of nearly 200 genes that can affect the cellular adaptive responses to 
hypoxia (Semenza et al., 2000).  
1.5.1 Regulation of HIF 
Investigation on the molecular mechanisms involved in hypoxia, and the induction of 
hematopoietic growth hormone EPO led to identification of HIF-1 by Semenza and 
Wang in 1992. The HIF system is discovered as a key regulator of a broad range of 
cellular and systemic responses to hypoxia and acts in all mammalian cells. Three 
isoforms of HIF-α exist (HIF-1α, HIF-2α, and HIF-3α). All are encoded by distinct gene 
loci and further diversity is generated by alternative splicing in the promotor region. HIF-
1α and HIF-2α share a similar domain structure and undergo similar proteolytic 
regulation; however, the tissue expression of HIF-2α seems to be more limited 
(Wiesener et al., 2003). HIF-1α-mediated pathways influence the processes of metabolic 
adaptation, erythropoiesis, angiogenesis, vascular tone, cell growth and differentiation, 
survival and apoptosis, and thus are critical factors in development, physiology, and 
disease (Maxwell et al., 2001). HIF-1α is a heterodimeric DNA-binding complex 
composed of two basic helix-loop-helix (HLH) proteins of the PER-ARNT-SIM (PAS) 
family, the constitutive HIF-1β and one of either hypoxia-inducible α-subunits, HIF-1α or 
HIF-2α (Wang et al., 1995). In hypoxia, the α/β heterodimer binds to a core sequence in 
the hypoxia response elements (HRE) of target genes. HIF-β subunit is a non-oxygen-
responsive nuclear protein that also has other roles in transcription, for example, in the 
xenobiotic response. In contrast, the HIF-α subunits are highly inducible by hypoxia. 
Under normoxic conditions, HIF-α subunits have a very short half-lives (Jewell et al., 
2001). Cells continuously synthesize and degrade HIF-1α protein. Oxygen-dependent 
degradation of HIF-1α is regulated by the hydroxylation of specific prolyl residues in a 
region of the peptide referred as the oxygen-dependent degradation (ODD). A family of 
2-oxoglutarate-dependent prolyl 4-hydroxylases is responsible for this event, which 
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requires O2, iron, 2-oxoglutarate, and ascorbate. The hydroxylated proline residues in 
the ODD domain of HIF-1α facilitate recognition by the von Hippel-Lindau (VHL) protein. 
VHL is the recognition component of an E3-ubiquitin ligase complex that targets HIF-1α 
for proteolysis by the ubiquitin–proteasome pathway (Ohh et al., 2000).  
 
 
 
 
Fig. 1 Regulation of HIF-1α under normoxia and hypoxia. Hypoxia or inhibitors that 
prevent HIF-1α degradation promote HIF-1α nuclear translocation and 
heterodimerization with HIF-1β. Oxygen-dependent hydroxylation by prolyl hydroxylases 
regulates the interaction with VHL and proteasomal degradation. 
 
 
Under hypoxic conditions, prolyl hydroxylation is suppressed, allowing HIF-1α subunit to 
accumulate, heterodimerize with HIF-1β, and initiate transcription. The effects of hypoxia 
HIF-1α 
O
O Prolyl 
hydroxylases 
HIF-1α 
VHL
HIF-1ß 
HIF-1α 
degradation 
Hypoxia 
2-Oxoglutarat analog 
(DMOG) 
Normoxia 
Ub 
Ub 
proteasome 
VHL
HIF-1α 
Hypoxia-inducible genes 
OH~ 
OH~ 
Ub 
Ub 
18 
 
can be mimicked by iron chelation, by use of 2-oxoglutarate analogs such as 
dimethyloxalyl glycine (DMOG) or by substitution of Fe(II) by metal ions such as cobalt. 
In contrast to regulation of HIF-1α stability by proline modification in the ODD, 
transcriptional activity is regulated by the hydroxylation of asparagine residues in the C-
terminal region of HIF-1α (Hewitson et al., 2002; Lando et al., 2002). 
1.5.2 Alternative modifications affecting HIF-1α transcription 
In addition to asparagine hydroxylation, various post-translational modifications occur on 
the HIF-1α C-terminal region, which can specifically modulate its activity. For example, 
phosphorylation of HIF-1α at Thr 796 by casein kinase II was first postulated by Gradin 
and coworkers (2002). Enhanced activation of mitogen-activated protein kinase p42/p44 
mediates phosphorylation of serine residues 641 and 643 and increases HIF-1α -
mediated transcriptional activity (Mylonis et al., 2006). Also, SUMOylation of HIF-1α has 
been suggested to increase HIF-1α stability and transcriptional activity (Carbia-
Nagashima et al., 2007). Another option for HIF-1α regulation can be by heat shock 
protein 90 (HSP90), a molecular chaperone that protects its target proteins from 
misfolding and degradation through its ATPase activity (Neckers et al., 2003). HSP90 
binds to the PAS domain of HIF-1α and increases its stability (Isaacs et al., 2004). Other 
stimuli for HIF-1α activation under normoxia include cytokines, growth factors, and 
oncogenes. 
1.5.3 Pharmacological manipulation of HIF-1α 
The central role of HIF-1α in physiology and pathophysiology makes it an attractive 
target for pharmacological manipulations. HIF-1α has an important role in triggering 
cellular protection and expression of genes involved in cell survival, apoptosis, and 
resistance to oxidative stress. For example HIF-dependent expression of glycolytic 
genes enhances ATP generation by anaerobic glycolysis. Similarly, HIF-dependent 
genes such as Heme Oxygenase-1 (HO-1) may regulate cell survival in I/R by affecting 
the response to oxidant stress. Other genes regulated by HIF-1α include inducible nitric 
oxide synthase (iNOS), which has been associated with enhanced resistance to 
ischemia in mice (Guo et al., 1999). Activators of HIF-1α might be useful for the 
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treatment of ischemic disease; however, inhibitors of HIF-1α could have some potential 
as anticancer therapeutics. Different strategies have been utilized to activate HIF-1α, 
where the best studied so far are inhibitors of the prolyl-hydroxylases (Warnecke et al., 
2003; Kim et al, 2006). Downregulation of PHD by siRNA in murine microvascular 
endothelial caused a time- and dose-dependent HIF-1α protein stabilization, 
corresponding with increase in iNOS mRNA. Treatment of intact murine hearts with 
siRNA directed against PHD2 produced a decrease in infarct size and cardiac 
dysfunction following global I/R. The improved functional recovery was lost in iNOS-/- 
mice (Natarajan et al., 2006). This study provides evidence that activation of HIF-1α 
inducible iNOS contributes to the protective effect against I/R. In vivo studies in a rabbit 
model of myocardial I/R showed that systemic administration of PHD inhibitor DMOG, 
before I/R is associated with a significant reduction in infarct size. The attenuation of 
tissue injury was associated with expression of HO-1, a gene regulated by HIF-1α 
(Ockaili et al., 2005). In both microvascular endothelium in vitro, and in vivo, DMOG 
attenuated interleukin 8 (IL-8) productions and this was associated with robust HO-1 
expression.These data show that HIF-1α activation induces HO-1 expression that is 
associated with attenuated proinflammatory chemokine production (Cai et al., 2008; 
Natarajan et al., 2007). Wild-type mice, or mice heterozygous to HIF-1α (HIF-1+/-) 
subjected to brief periods of ischemia, followed by 30 min of continuous ischemia 
showed improved infarct size and function after I/R in wild-type animals, but not in HIF-
1+/- hearts. This suggests that HIF-1α activation should confer protection against I/R 
injury, although this protection might require HIF-1α activation before the onset of lethal 
ischemia. Moreover, two isoforms of the α subunit with high sequence homology, HIF-1α 
and HIF-2α, have been identified. Research (Hill et al., 2008) with mice heterozygous for 
a defect in either HIF-1α or HIF-2α provide direct evidence that both subunits have 
protective roles in the renal I/R injury. Similarly, a recently reported study showed that a 
HIF hydroxylase inhibitor with non-disclosure name FG-4487 (FibroGen), protected the 
rat from renal I/R injury and also induced accumulation of both HIF-1α and HIF-2α 
subunits (Bernhardt et al., 2006). Taken together, all this finding provide evidence that 
both HIF-1α and HIF-2α isoforms when activated predispose to protection against I/R 
injury. In this context, up-regulation HIF appears to play an important role in the 
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protection against injury. However, the molecular mechanisms responsible for this 
protection are still under intensive investigation.  
1.6 Alternative regulators  
1.6.1 Regulation of p53  
HIF-1α as well as p53 are transcription factors involved in stress responses which 
require an immediate reaction of the affected cell (Schmid et al., 2004). Normally, p53 
controls cellular homeostasis by affecting cell cycle progression and apoptosis. In 
unstressed cells p53 exhibits short half-life and the protein amount is maintained at a 
low level. Under stress such as DNA damage, nutrient deprivation, or hypoxia, p53 
(Levine et al., 2006) is stabilized mainly by posttranslational modification. p53 becomes 
active as a transcription factor and promotes transcription of cell cycle regulating genes 
such as p21WAF1/CIP1, mouse doubles minute 2 (Mdm2) as well as genes involved in 
apoptotic events like Bax, Fas, Bid (Vousden and Lu 2002). Each of these genes when 
silenced or removed induces partial resistance to p53-induced apoptosis. Mechanisms 
responsible for p53 inactivation include the regulation of protein activity, stability and 
subcellular localization. Different enzymes involved in post-translational modification of 
p53 such as ataxia telangiectasia, rad-3-related kinase (ATR) kinase as well as 
transcriptional coactivators can modulate the transcriptional activity of p53 (Boyd et al., 
2000; Shieh et al.,1997; Shirangi et al., 2002). Protein stability of p53 can be regulated 
by  ubiquitin ligases. This is illustrated by Mdm2, one of the key E3-ubiquitin ligases 
responsible for limiting the levels of p53 (Harris and Levine, 2005). Deletion of Mdm2 in 
mice results in an extremely early embryonic lethality that is the direct result of impeding 
p53-mediated apoptosis. Negative regulation of p53 is accomplished by Mdm2, either 
through ubiquitin-dependent p53 degradation in the cytoplasm (Haupt et al., 1997; 
Honda et al., 1997; Kubbutat et al., 1997) or repression of p53 transcriptional activity in 
the nucleus (Thut et al., 1997). Both, Mdm2 and p53 are nuclear proteins that shuttle 
constantly through the nuclear pore complex. Mdm2 and p53 are translocated between 
the cytoplasm and the nucleus by their intrinsic nuclear localization signal (NLS) and 
nuclear export signal (NES) sequences (Chen et al., 1995; Liang and Clarke, 2001; Roth 
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et al.,1998). Blocking their nuclear export by mutations in the NES or by leptomycin B 
leads to their stabilization, indicating that both Mdm2 and p53 are degraded in the 
cytoplasm (Freedman and Levine 1998). A recent study demonstrating that 
phosphorylation at the p53 N-terminal inhibits its nuclear export, emphasizes the 
importance of export in controlling p53 function (Zhang et al., 2001). 
All these signals affecting p53 suggest that each stress response utilizes a different 
pathway to induce a p53 response. For example reduced expression of alternate 
reading frame (ARF), a small protein that inhibits Mdm2  leads to stabilization of p53. 
1.6.2 HIF-1α-p53-interplay 
p53 like HIF-1α, is continuously expressed and immediately marked for degradation by 
specific E3-ubiquitin ligases: Mdm2 and VHL consequently. HIF-1α and p53 are kept at 
low levels during normoxia. HIF-1α is hydroxylated under normoxic conditions, 
subsequently bound by VHL and marked for proteasomal degradation by ubiquitination. 
Under hypoxic conditions, HIF-1α accumulates, binds to the transcriptional cofactor 
cAMP-response element-binding protein (CBP/p300) and induces expression of HIF-1α  
target genes. A similar process takes place during normoxia, where p53 is bound and 
targeted for degradation by Mdm2. During hypoxia, the interaction between Mdm2 and 
p53 can be impaired by phosphorylation of p53 by ATR kinase or through Mdm2 
downregulation, which prevents binding of Mdm2 and allows accumulation of p53. Then 
p53 binds CBP/p300 and becomes transcriptionally active. The illustrated regulation via 
constant synthesis of protein becomes understandable when the function of both 
proteins is taken into account. Competition between p53 and HIF-1α for limiting amounts 
of the shared transcriptional coactivator CBP/p300 (Freedman et al., 2002) can explain 
how transcriptional activity of both p53 and HIF-1α might be affected, depending on the 
relative amount of either factor. An and coworkers (1998) demonstrated that p53 
stabilization under hypoxia is dependent on HIF-1α, either directly (Hansson et al., 2002) 
or via Mdm2 (Chen et al., 2003). Such interactions resulted in p53 stabilization and 
activation, and concomitantly, HIF-1α degradation. This illustrates that p53 also seems 
to play a pivotal role in HIF-1α regulation. In line with these observations are reports 
showing that p53 inhibits HIF-1α activity by targeting HIF-1α for Mdm2-mediated 
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ubiquitination and proteasomal degradation (Ravi et al., 2000). In turn, the loss of p53 
has been shown to enhance hypoxia-induced HIF-1α levels. Besides directly affecting 
HIF-1α protein level, p53 represses HIF-1α-stimulated transcription (Ravi et al., 2000). 
Interestingly, p53 levels required to affect HIF-1α were higher than those needed for 
p53-activated gene transcription (Blagosklonny et al., 1998). In endothelial cells p53 
activation by hypoxia is partly independent of HIF-1α. This could explain particularly high 
levels of inactive p53 by the fact that regulation in endothelial cells is different 
(Sabapathy et al., 1997). The above observation supports the concept that similar and in 
many cases common regulatory mechanisms exist that regulates the transcriptional 
activity and protein stability of both HIF-1α and p53. Therefore, the present study aims to 
further elucidate the impact of HIF-1α on p53, specifically focusing on cell survival and 
H/R injury. 
1.7 Mdm2 
1.7.1 Regulation of Mdm2  
Mdm2 gene encodes a protein with a predicted molecular weight of 56 kDa. This protein 
contains several conserved structural domains including the N-terminal p53 interaction 
domain. Mdm2 also contains  C-terminal RING domain, which confers E3-ubiquitin 
ligase activity. There are several known mechanisms for Mdm2 regulation (Meek et al., 
2003). One of these mechanisms is phosphorylation of the Mdm2 protein. Mdm2 is 
phosphorylated at multiple sites by Protein kinase B, Death-associated protein kinase, 
cyclin dependent kinase and ATR kinase. Following DNA damage, phosphorylation of 
Mdm2 leads to changes in protein function and stabilization of p53. Additionally, 
phosphorylation at certain residues of Mdm2 may stimulate its ability to target p53 for 
degradation. The induction of ARF product of the p14arf protein is also a negative 
regulator of p53-Mdm2 interaction. It interacts directly with Mdm2 leading to up-
regulation of p53 transcriptional response. ARF captures Mdm2 in the nucleus, resulting 
in inhibition of nuclear export and activation of p53, since nuclear export is essential for 
proper p53 degradation. The Mdm2 gene is in turn transcriptionally activated by p53, 
constituting a feedback regulatory loop (Christophorou et al., 2006). 
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1.8 HIF-1α and Mdm2 interplay  
Recent reports confirmed an association between endogenous Mdm2 and HIF-1α under 
conditions of oxygen deprivation that results in increased physiologically-regulated levels 
of HIF-1α (Nieminen et al., 2005). Furthemore, under hypoxia, HIF-1α directly binds to 
Mdm2 both in vitro and in vivo, thereby stabilising p53 (Chen et al., 2003). Thus, Mdm2 
expression significantly induces the indirect interaction between p53 and HIF-1α in cells, 
indicating that Mdm2 may act as a bridge, mediating the p53-HIF-1α interaction.  
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1.9 Working hypothesis 
Hypoxia, H/R, and chronic hypoxia are all capable of engaging cellular death pathways 
leading to tissue injury and organ dysfunction. In the present study we focus on ongoing 
apoptosis during H/R in endothelial cells. It is well established that HIF-1α may play a 
role in H/R-induced injury of endothelial cells. HIF-1α is the principal regulator of cellular 
transcriptional responses to hypoxia. However, HIF-1α is degraded during 
reoxygenation, which may limit its effect on cell survival during the hypoxic period only. 
 
 
Fig. 2 These schematic diagrams illustrate the progression of apoptosis (upper panel) in 
relation to HIF-1α expression (lower panel) during hypoxia and reoxygenation. 
It was hypothesized that a maneuver that stabilizes HIF-1α beyond the period of hypoxia 
may protect endothelial cell against ongoing apoptotic cell death during H/R. To further 
elucidate the function of HIF-1α, DMOG, 2-oxoglutarate analog, an inhibitor of PHD, was 
given at the onset of reoxygenation, an approach termed ‘pharmacological 
postconditioning’ (Hausenloy et al., 2005).  
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Fig. 3 Effect of the hypothesized pharmacological postconditioning mediated through 
prolyl-hydroxylase inhibition applied at the onset of reoxygenation leading to HIF-1α 
stabilization (dotted line lower panel). As a result endothelial cell apoptosis during 
reoxygenation is inhibited (dotted line upper panel). 
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1.10 Aims of the study 
The present study was conducted to elucidate the molecular mechanism by which 
inhibition of PHD pathway leads to protection of endothelial cells against ongoing 
apoptotic cell death during H/R. Since previous studies using preservation of HIF-1α 
suggest its beneficial therapeutic potential in the treatment or prevention of ischemic 
injury, the present study was focused to analyse the molecular mechanism by which 
stabilization of HIF-1α exerts anti-apoptotic effects during H/R. The study was performed 
using an established model of cultured monolayers of human umbilical vein endothelial 
cells (HUVEC). The following questions were addressed: 
 
Does inhibition of PHD protect endothelial cells against ongoing apoptotic cell death 
during H/R? 
 
Does inhibition of PHD cause pro-apoptotic p53 protein degradation? 
 
Is this p53 downregulation dependent on HIF-1α stabilization? 
 
Does stabilization of HIF-1α regulate Mdm2, a specific E3-ubiquitin ligase? 
 
Is this ligase responsible for p53 destabilization? 
 
Does HIF-1α induce p53 degradation mediated by Mdm2? 
 
 
As a pro-apoptotic challenge endothelial cells were cultured in serum free medium for 12 
h and subjected to hypoxia for 1 h followed by reoxygenation. Under this condition, the 
effect of HIF-1α was analysed. 
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2 MATERIALS 
 
2.1 Chemicals and consumables 
 
Acrylamide solution (40%; wt/vol)  Amersham Pharmacia, Bucks 
Acrylamide    Carl Roth, Karlsruhe 
Ammonium persulfate             SERVA, Heidelberg 
Annexin V FITC-Apoptosis   BD-Pharmingen, Heidelberg 
Benzonase    Merck, Darmstadt 
bFGF                    PromoCell, Heidelberg  
Bisacrylamide solution (2%; wt/vol)    Amersham Biosciences, Buckinghamshire, UK 
Bisacrylamide             Carl Roth, Karlsruhe 
Bovine serum albumin (BSA)     Sigma-Aldrich, Steinheim 
Bromophenol blue          Sigma-Aldrich, Steinheim 
Calcium chloride            Merck, Darmstadt 
Collagenase II               PAA, Pasching  
Complete® protease inhibitor cocktail  Roche, Mannheim  
Culture dishes    BD-Pharmingen, Heidelberg 
Dimethyloxallyl Glycine (DMOG)       Cayman, Michigan, USA 
Dimethyl sulfoxide (DMSO)        Sigma-Aldrich, Steinheim  
Di-sodium hydrogen phosphate      Carl Roth, Karlsruhe  
Dithiothreitol (DTT)  Amersham Biosciences, Buckinghamshire, UK 
Chemiluminescent Substrate      Pierce Biotechnology, Rockford, USA 
EDTA                  Carl Roth, Karlsruhe  
EGTA               Boehringer, Mannheim 
Endothelial cell basal medium®     PromoCell, Heidelberg  
Endothelial cell growth supplement    PromoCell, Heidelberg  
Eppendorf tubes (0.5, 1.5, 2 ml) Eppendorf, Hamburg 
FACS tubes           BD-Pharmingen, Heidelberg 
FACS Flow                 BD-Pharmingen, Heidelberg 
Falcon tubes (50 ml, 12 ml)      BD, Heidelberg 
Fetal Calf Serum (FCS) PAA, Pasching 
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Filter papers      Biotech-Fischer, Reiskirchen 
FuGENE® 6               Roche, Mannheim  
Glass coverslips            Menzel, Braunschweig  
Glycerol (100%)             Sigma-Aldrich, Steinheim  
Glycine   Carl Roth, Karlsruhe 
HBSS               PAA, Pasching 
hEGF                  PromoCell, Heidelberg 
HEPES                  Sigma-Aldrich, Steinheim 
Hydrocortisone              PromoCell, Heidelberg 
Magnesium chloride          Fluka, Buchs, Switzerland 
Magnesium sulfate    Merck, Darmstadt 
ß-mercaptoethanol           Merck, Darmstadt 
Methanol               Merck, Darmstadt 
Millipore water    Millipore, Eschborn 
MG-132 Biomol, Plymouth Meeting, USA 
Molecular weight marker          Sigma-Aldrich, Steinheim 
Nitrocellulose membrane          Schleicher & Schuell, Dassel 
Nitrogen (100%)        Liquid, Krefeld 
Non-fat milk powder   Applichem, Darmstadt 
Nonidet P-40     Sigma-Aldrich, Steinheim 
Paraformaldehyde         Sigma-Aldrich, Steinheim 
Parafilm®                Pechiney Plastic Pack, Menasha, USA 
Penicillin/streptomycin         Gibco BRL, Eggenstein 
Phosphate buffered saline (PBS)   Gibco BRL, Eggenstein 
Pifithrin-α (PFT-α)    Sigma-Aldrich, Steinheim 
Pipette tips    Eppendorf, Hamburg 
Pipettes      Eppendorf, Hamburg 
PMSF      Sigma-Aldrich, Steinheim 
Ponceau S solution        SERVA, Heidelberg 
Potassium chloride    Merck, Darmstadt 
Potassium dihydrogen phosphate    Merck, Darmstadt 
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Protein G-coated magnetic beads  Dynal,  Oslo, Norway 
Primary cell culture dishes    BD Falcon, Heidelberg 
Rubber policeman             BD, Heidelberg 
Scalpel (disposble)              Feather, Japan 
See Blue® (pre-stained marker)   Invitrogen GmbH, Karlsruhe 
Sodium azide                  Merck, Darmstadt 
Sodium chloride                                 Carl Roth, Karlsruhe  
Sodium orthovanadate       Sigma-Aldrich, Steinheim 
Sodium di-hydrogen phosphate   Carl Roth, Karlsruhe 
Sodium dodecyl sulfate (SDS)     SERVA, Heidelberg 
Sodium fluoride             Sigma-Aldrich, Steinheim 
Sodium hydroxide             Carl Roth, Karlsruhe 
Sodium orthovanadate         Sigma-Aldrich, Steinheim 
Sterile filters (0.22 μm)         Sartorius, Goettingen 
Sterile pipettes                 BD, Heidelberg 
Super signal-west®         Pierce biotech, Bonn 
Syringes (20 ml, 2 ml)          BD, Heidelberg 
TEMED                Sigma-Aldrich, Steinheim 
TOPRO-3            Invitrogen GmbH, Karlsruhe 
Trypsin-EDTA           Gibco-BRL, Eggenstein 
Tris base              Carl Roth, Karlsruhe 
Tritone X-100            Gibco-BRL, Eggenstein 
Tween 20                  Amersham Biosciences, Buckinghamshire, UK 
Whatman® 3 MM filter paper  Millipore, Eschborn 
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2.2. siRNAs  
 
1. Control siRNA duplex negative Eurogentec, Seraing, Belgium 
 
2. HIF-1α sc-44225 Santa Cruz Biotechnology, Heidelberg, Germany 
target sequence (target sequence: CGAGGAAGAACUAUGAACA) 
target sequence (GAAUCAGAAGAUACAAGUA) 
target sequence (CGAUGGAAGCACUAGACAA) 
 
3. PHD2 (EGLN 1) ON-Target plus SMARTpool, Fischer Scientific, Germany 
target sequence (GCGAUAAGAUCACCUGGAU) 
target sequence (GACCUGAUACGCCACUGUA) 
target sequence (GCUCAUCGCUGUUCCAGGA) 
target sequence (GAACAAGCACGGCAUCUGU) 
 
4. Mdm2  sc-29394 Santa Cruz Biotechnology, Heidelberg, Germany 
target sequence (GCUUCGGAACAAGAGACCC) 
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2.3 Antibodies 
 
 
Primary antibodies: Manufacture Dilution 
 
HIF-1α (Mouse)    BD Bioscience, Heidelberg   1:250 
Mdm2 (N-20) (Rabbit)  Santa Cruz Biotechnology, USA  1:1000 
p53 (DO-1) (Mouse)      Santa Cruz Biotechnology, USA  1:1000 
PHD2 (Rabbit)    Novus Biologicals, Hiddenhausen   1:1000 
Vinculin (hVIN-1) (Mouse)   Sigma, Steinheim    1:2000 
 
 
Secondary antibodies: 
 
Mouse IgG-HRP  BD Bioscience, Heidelberg     1:2000 
Rabbit IgG-HRP    Upstate, Charlottesville, USA   1:2000 
Mouse IgG (H+L) Alexa Fluor 488   Invitrogen, Karlsruhe      1:400 
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2.4 Laboratory equipment 
 
Beckman Allegra 64R centrifuge Beckman Coulter, Fullerton 
Beckman TL 100 ultracentrifuge   Beckman Coulter, Fullerton 
Blotting chambers     Biotech-Fischer, Reiskirchen 
Confocal Microscope LSM 510    Carl Zeiss AG, Oberkochen 
counter                Packard Instrument Company CT, USA 
Electrophoresis apparatus         Biometra, Goettingen 
FACS Calibur®              BD Bioscience, Heidelberg 
Gel documentation system      Quantity One series Bio-Rad, Munich 
Glass ware              Schott, Mainz 
Hamilton syringe    Hamilton, Bonaduz 
Heatblock    Techne, Burkhardtsdorf 
Hypoxia-Chambers           workshop Institute of Physiology  of JLU 
Incubators                          Heraeus, Hanau 
Laminar flow hood      Heraeus, Hanau 
Magnet stirrer   Jahnke und Kunkel, Staufen 
Magnetic rack    DYNAL, Oslo, Norway 
Neubauer chamber           Superior, Marienfeld 
Phase contrast microscope      Olympus, Japan 
pH-Meter              WTW-Weinheim 
Photometer              Carl Zeiss, Jena 
Power supply            Biometra, Goettingen 
Rocker     Biometra, Goettingen 
Table top (centrifuge)    Eppendorf, Hamburg 
Vortexer     Heidolph, Kelheim 
Water bath   Julabo, Seelbach 
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3 METHODS 
 
3.1 Isolation and cultivation of human umbilical vein endothelial cells 
 
HUVEC were isolated from freshly collected umbilical cords (from Gynecology 
Department, University Hospital Giessen). To isolate HUVEC the vein in the umbilical 
cord was canulated and rinsed with warm HBSS supplemented with 1.3 mM CaCl2 and 
1.2 mM MgCl2. To detach the endothelial cells from the vessel wall, the umbilical cord 
vein was incubated with collagenase II A solution in a humidified incubator for 20 min. 
The primary endothelial cells were then washed out of the vessel with HBSS containing 
3% (vol/vol) FCS, added to inactivate collagenase activity. Following collection of the 
cells, they were pelleted by centrifugation at 250 x g for 5 min at RT. The supernatant 
was discarded and cells were resuspended in endothelial cell culture medium and 
seeded into 3-4 primary cell culture dishes. After incubation for 2 h at 37 °C and 5% 
CO2, cells were extensively washed with HBSS to remove unattached non–endothelial 
cells and cell debris. Adherent cells were incubated in 15-20 ml of cell culture medium at 
37 °C and 5% CO2 in a humidified incubator. After 24 h the medium was replaced with 
fresh cell culture medium. The cells were passaged and maintained in HUVEC growth 
medium with 20% (vol/vol) FCS at 37 °C with 5% CO2 in a humidified incubator.  
 
 
Endothelial cell culture medium 
 
Endothelial cell basal medium (PromoCell®) supplemented with FCS (vol/vol) 10% 
Endothelial cell growth supplement/Heparin (wt/vol)           0.4% 
Hydrocortisone (wt/vol)                      0.1% 
bFGF                           1 ng/ml 
hEGF                           0.1 ng/ml 
Penicillin/streptomycin (vol/vol)    2% 
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Collagenase solution 
 
HBSS                             x ml 
Collagenase II, 293 IU/mg (wt/vol)                  0.025% 
MgCl2     0.5 mM 
CaCl2      1.5 mM 
 
 
3.2 Subcultivation of endothelial cells 
 
Confluent monolayer of primary endothelial cells were trypsinized 5-7 days after 
seeding. Cells were washed once with warm HBSS followed by incubation with trypsin-
EDTA (Composition in mM: 137 NaCl, 2.7 KCl, 1.5 KH2PO4, 8.0 Na2HPO4; pH 7.4, 
0.05% (wt/vol) trypsin and 0.02% (wt/vol) EDTA) for approximately 2 min to allow the 
majority of the cells to detach from the cell culture dish. Trypsinized cells were collected 
into cell culture medium and seeded at a density of 5.5 x 104 cells/cm2 on 35 mm dishes, 
(according to the experiment being performed). For immunostaining and confocal 
microscopy cells were seeded onto 25 mm glass coverslips. Experiments were 
performed with confluent endothelial monolayers of passage 1, 3-4 days after seeding. 
 
 
3.3 Experimental protocol for hypoxia/reoxygenation  
 
Confluent monolayers of HUVEC were cultivated in serum free culture medium 12 h 
before onset of experiments. After an initial 
equilibration period of 15 min in HBSS 
supplemented with 1.3 mM CaCl2, 1.2 mM 
MgCl2, and 0.05% (wt/vol) bovine serum 
albumin (BSA), cells were subjected to 1 h of 
hypoxia (Po2 < 10 mmHg) in an air tight 
chamber flushed with 100% humidified N2, 
followed by 24 h of reoxygenation. Normoxic controls were exposed to humidified air 
(Po2 = 140 mmHg). 
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To investigate the effect on cell signaling and ongoing apoptotic cell death, 
pharmacological inhibitors were added with the onset of reoxygenation. Stock solutions 
of inhibitors were prepared immediately in DMSO. Appropriate volumes of these 
solutions were added to the cells yielding in a final concentration < 0.1% (vol/vol). In a 
set of pilot experiments concentration-response relationships were determined to find 
the optimum effective concentration of the inhibitors used in this study. They were 
applied in their optimum effective concentrations. 
 
 
 
 
Starvation media 
 
Endothelial cell basal medium (PromoCell®)  
supplemented with Penicillin/streptomycin (vol/vol) 2% 
 
Basal media for hypoxia/normoxia (H/N) 
 
HBSS supplemented with 1.3 mM CaCl2, 1.2 mM MgCl2, and 0.05% (wt/vol) BSA 
 
 
 
 
 
 
Serum deprivation
Normoxia 
Normoxia Hypoxia Reoxygnation + inhibitor 
-12  0 1 24
Time (h) 
Normoxia Hypoxia Reoxygnation 
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List of pharmacological inhibitors 
 
Inhibitor Inhibiting protein concentration  
used 
Solvent 
DMOG 1 mM DMSO 
MG-132 10 µM DMSO 
PFT-α 100 µM DMSO 
 
 
3.4 siRNA interference  
 
Knockdown of endogenous HIF-α, PHD2, and Mdm2 was achieved by transfection of 
specific siRNA and transfection agent Fugene 6 according to manufacture’s instructions.  
Protocol: 24 h prior to experiments 70-80% confluent cell monolayers were transfected 
with 2 µl of Fugene 6 to 97 µl of OPTI-MEM using 1-2 µg of siRNA. After 6 h 10% 
(vol/vol) FCS was added. Control samples were treated with identical concentration of 
non-specific siRNA following the same protocol. 
 
 
3.5 SDS polyacrylamide gel electrophoresis (SDS-PAGE) 
 
Sample preparation: Endothelial cells  were washed with HBSS and subsequently 
lysed in 150 μl 1 x SDS sample buffer and 10 mM DTT added freshly before use. 
Subsequently, 50 IU/ml Benzonase® and 2 mM MgCl2 was added and the lysate was 
collected in a 1.5 ml Eppendorf tube. Samples were denatured for 3 min at 95 °C and 
used immediately or stored at –20 °C. 
Procedure: Discontinuous SDS polyacrylamide gel electrophoresis (Laemmli 1970) was 
performed to analyse protein content in cell lysates. The resolving gel solution, 
composition is given below, was poured into the assembled gel mold between two glass 
plates separated by 1 mm thick spacers leaving about 1 cm space for the stacking gel 
solution and layered with water. After polymerization the water was removed, the 
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stacking gel solution was poured on top and the comb was inserted. After polymerization 
of the stacking gel, the comb was removed and the gel mounted in the electrophoresis 
chamber. Electrode reservoirs were filled with 1 x SDS running buffer, the wells were 
cleaned and samples loaded. Electrophoresis was run overnight at 45 V.  
 
1x-SDS sample buffer 
 
Tris/HCl (pH 6.8)   2.5 mM  
Glycerol               5% (vol/vol) 
SDS        2% (wt/vol) 
DTT               1 mM  
ß-mercaptoethanol        0.9% (vol/vol) 
Bromophenol Blue     0.002% (wt/vol) 
 
 
Resolving gel buffer: Tris/HCl; pH 8.8     1.5 M 
Stacking gel buffer: Tris/HCl; pH 6.8     0.5 M 
 
 
10x Gel running buffer 
 
Tris                   250 mM 
Glycine                2.0 M 
SDS (wt/vol)               10% 
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3.6 Western blot  
 
Proteins were separated by 7,5-15% SDS-PAGE and electro-transferred onto a 
nitrocellulose membrane at 0.8-0.9 mA/cm2 for 120 min using a semi-dry blot system. 
For this, the nitrocellulose membranes together with filter papers (Whatman® 3 MM 
filter) were soaked in transfer buffer (25 mM Tris, 150 mM Glycin, 10% Methanol, pH 
8.3). The membrane and filters were stacked as a “sandwich” in the following order: filter 
paper, membrane, gel, and filter paper. To check for equal amounts of protein and 
successful blotting, the membrane was incubated with Ponceau S, a reversible protein 
staining solution. The membrane was washed in millipore water to the desired contrast 
and photographed. To remove the stain completely the membrane was washed with 1 x 
TBST. To prevent unspecific binding of the antibodies the membrane was blocked with a 
blocking buffer depending on the antibody to be used for 1 h at RT. After blocking, the 
membrane was incubated with the primary antibodies diluted in their respective blocking 
buffer BSA or Milk for 1 h at RT or at 4 °C overnight. Unbound antibody was removed by 
washing 3 x 5 min with TBST. The membrane was then incubated for 1 h at RT with a 
secondary antibody conjugated with horseradish peroxidase. After washing 3 times as 
described above, the enzyme activity was detected by use of enhanced 
Resolving gels Stacking gel Gel 
Solutions     7.5 %  10 %   12.5 %  15 %     6 % 
Acryl. 40% (wt/vol) 7.7 ml  10.2 ml 12.7 ml 15.3 ml   3.8 ml 
 Bisacryl.2%(wt/vol) 4.2 ml  5.6 ml  7.0 ml   8.4 ml     2.0 ml 
 
Millipore water   17.7 ml 13.8 ml  9.8 ml   5.8 ml     17.5 ml 
  Resolving gel buff. 9.5 ml  9.5 ml   9.5 ml   9.5 ml     ------ 
Stacking gel buff.  ------  ------   ------   ------     6.0 ml 
 
SDS 10%(wt/vol)  0.4 ml  0.4 ml  0.4 ml  0.4 ml     0.25 ml 
 
TEMED     30 μl  30 μl   30 μl   30 μl      20 μl 
APS 10% (wt/vol)  0.4 ml   0.4 ml  0.4 ml  0.4 ml     0.25 ml 
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chemiluminescence (ECL) according to the supplier’s protocol with a bioluminescence 
detection system and recorded with Bio-Rad Quantity One gel documentation system. 
 
10x Tris-buffered saline  (TBS) 
 
Tris/HCl (pH 7.4)    100 mM 
NaCl          1.6 M 
 
TBS Tween (TBST) 
 
1 x TBS 
0.1% (vol/vol)      Tween 20 
 
Blocking-buffer and antibody-dilution buffer 
 
3% (wt/vol) BSA in 1 x TBST or 
5% (wt/vol) nonfat dry milk powder in 1 x TBST (Milk) 
 
 
3.6.1 Stripping membranes  
 
For removing primary and secondary antibodies from the membrane, blots were 
incubated in stripping buffer shaking for 2 min at 60 °C. After six washing steps (5 min in 
TBST at RT), the membrane was blocked for 1 h with 5% nonfat dry milk (in TBST) 
before detection with another primary antibody. 
 
Stripping buffer 
 
Tris/HCl (pH 6.8)         62.5 mM 
SDS            2% (wt/vol) 
β-mercaptoethanol     0.8% (vol/vol) 
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3.7 Immunoprecipitation 
 
Preparation of beads: Protein G-coated magnetic beads (6 μl beads suspension for 
approximately 1 mg of total cell lysate) were washed 3-4 times with 0.1 M 1 x PBS 
(Composition in mM: 137 NaCl, 2.7 KCl, 1.5 KH2PO4, 8.0 Na2HPO4; pH 7.4) and 
incubated with the respective antibody (4-5 μg for 1 mg total cell lysate) overnight at 4 
°C with end-over-end rotation. Afterwards the beads were washed 3-4 times with 0.1 M 
sodium phosphate buffer containing 0.1 % (vol/vol) Tween 20 and stored in 50 μl of 1 x 
PBS. 
 
Protocol: Confluent endothelial monolayers cultured on 10 cm dishes, subjected to 1 h 
hypoxia and reoxygenated in absence or presence of different inhibitors as indicated in 
the text, were incubated in 500 µl lysis buffer for 10 min on ice and subsequently 
harvested by scraping with a rubber policeman. Cells were further lysed by using a 27 G 
needle and 1 ml syringe, 4-6 times. The lysate was centrifuged at 1000 x g for 5 min at 4 
° C. The supernatant was transferred to another tube and incubated with the respective 
antibodies pre-immobilized on protein G-coated magnetic beads for 1.5 h at 4 °C on a 
permanent rotator. After incubation, beads were washed 3 times with 1 x PBS containing 
0.1 % (vol/vol) Tween 20. Finally, the precipitates were detached from the G-coated 
magnetic beads by application of hot SDS-sample buffer and heated for 5 min at 90 °C. 
Proteins were detected and analysed by SDS-PAGE and Western blot. 
 
 
10x PBS 
 
Na2HPO4            0.1 M 
KH2PO4             17 mM 
NaCl               1.37 M 
KCl    27 mM 
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Lysis buffer Immunoprecipitation 
 
Tris/HCl (pH 7.4)    50 mM 
NaCl              150 mM 
Triton X-100            1% (vol/vol) 
Nonidet P 40       0.5% (vol/vol)  
EDTA      1 mM 
EGTA            1 mM 
NaF            20 mM 
Na-orthovanadate       1.5 mM 
DTT        10 mM 
PMSF   0.5 mM 
Complete ®         10 ml 
 
 
3.8 Nuclear and cytoplasmic protein extraction 
 
Endothelial cell monolayers (2-4 106 cells per 10 cm dish) were washed with 1 x PBS 
and then resuspended in 500 μl hypotonic buffer A (containing 10 mM HEPES pH 7.9, 
10 mM KCl, 0.1 mM DTT, 0.1 mM EDTA, 0.5 mM PMSF, and 1 tablet of proteinase 
inhibitor) and incubated for 10 min on ice before adding NP-40 to a final concentration of 
0.6% (vol/vol) vortexed, and centrifugated at 13.000 x g for 15 min. The supernatant 
contained the cytoplasmic fraction. The pellet was washed with buffer A and 
resuspended in 150 μl high salt buffer B (containing 20 mM HEPES pH 7.9, 400 mM 
NaCl, 0.1 mM DTT, 1 mM EDTA, 10% glycerol (vol/vol), 0.5 mM PMSF, and 1 tablet of 
proteinase inhibitor). The pellet was incubated at 4 °C on a full speed shaker for 2 h. 
After incubation, the suspension was centrifugated at 13.000 x g at 4 °C for 5 min. The 
supernatant contained the nuclear fraction. Protein concentration of the nuclear and 
cytoplasmic extracts was determined by Bradford. 
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3.9 Determination of protein concentration by Bradford  
 
The Bradford assay was used to determine the concentration of proteins in a solution. 
The assay reagent was prepared by diluting 1 volume of the dye stock with 4 volumes of 
distilled H2O. BSA was used a standard. Both, the standard and the samples were 
prepared in PBS and 1 ml assay reagent was mixed with 20 μl sample or standard. After 
5 min incubation time they were measured at 595 nm absorbance in an ELISA reader 
(spectrophotometer).  
 
3.10 FACS analysis 
 
The effect of hypoxia, reoxygenation, and different pharmacological treatments on 
endothelial cell apoptosis was determined by Fluorescence-activated cell sorting (FACS) 
by analysing of Annexin V-FITC and propidium (PI) staining according to manufacture’s 
instructions. Annexin V and PI were added to trypsinized and suspended cells. Samples 
of 10.000 cells were analysed by flow cytometry on FACS-Calibur using CELLQuest Pro 
software. Cells that were Annexin V-FITC positive were identified as apoptotic, while 
cells that were PI positive and Annexin V negative were identified as necrotic. 
Nonstained cells were identified as vital. 
 
3.11 Immunoflorescence 
 
After stimulation on of endothelial monolayers on glass coverslips, cells were washed 3 
times with 1 x PBS. Thereafter, cells were fixed in 4% (wt/vol) paraformaldehyde (PFA) 
for 20 min at 37 °C and washed 3 times with 1 x PBS. Cells were then permeabilized 
with 0.1% (vol/vol) Triton X-100 for 7 min and additionally washed another 3 times with 1 
x PBS. Subsequently, fixed and permeabilized HUVEC were blocked with blocking 
solution 5% (wt/vol) GFCFS, 5% (wt/vol) BSA, 1 x PBS for 60 min at RT. Samples were 
incubated for 3 h at 37 °C or 4 °C overnight with primary antibody (in blocking solution 
containing 0.1% (vol/vol) Tween 20, dilution 1:200). Afterwards, samples were washed 4 
times with 1 x PBS and incubated for 60 min at RT with 1:400 Alexa-Fluor 488 tagged 
secondary antibody in blocking solution and kept in dark. 
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Nuclear staining was performed by incubating cells with TOPRO-3 (1:200) dilution in 1 x 
PBS for 15 min. Following final washing for 3 times with 1 x PBS in dark, coverslips were 
taken from dishes and were fixed with mounting medium (1 x PBS/100% glycerol 
(vol/vol) 1:1) on a microscopic slide. After storing overnight, the cells were analysed with 
a Zeiss LSM 510 confocal laser scanning microscope. 
 
3.12 Statistical analysis  
 
All statistical analysis were performed using Sigma Stat version 8.0. For comparison of 
two normally distributed groups of data, the Student’s t-test was used. For multiple 
comparisons of normal distributed data the one-way analysis of variance (one-way 
ANOVA) was used. For descriptive purposes all data are presented as means ± the 
standard error of means. Results were considered significant at an error probability level 
of P < 0.05. 
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4 RESULTS 
4.1 Effect of DMOG on endothelial apoptosis during reoxygenation 
There is evidence that infarct size and cardiac dysfunction following global I/R is 
decreased after inhibition of PHD either by treatment with the inhibitor DMOG (Ockaili et 
al., 2005) or silencing with siRNA (Natarajan et al., 2006). In adition, it has been shown 
that HIF-1α is a key factor in ischemic preconditioning-induced cardioprotection (Cai et 
al., 2008).  
First it was proven whether inhibition of PHD with DMOG during reoxygenation protects 
endothelial cells against apoptosis induced by serum starvation. HUVEC were cultured 
in serum-free medium for 12 h and exposed to 1 h of hypoxia. Endothelial cells were 
analysed for apoptotic cell death by FACS analysis after 24 h of reoxygenation in 
absence of serum. 
As shown in Fig. 1 serum deprivation induced apoptotic cell death in 60% of the total cell 
population that was not significantly reduced in those cells exposed to 1 h of hypoxia. 
However in presence of DMOG during reoxygenation reduced apoptosis by 50%. 
Correspondingly, cell number of vital cells was increased by inhibition of PHD. These 
data indicate that DMOG reduces serum starvation-induced apoptotic cell death when 
added at the onset of reoxygenation. 
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Fig. 1 Effect of DMOG during reoxygenation on serum starvation-induced apoptosis. 
HUVEC were serum deprived for 12 h. Afterwards, cells were exposed to 1 h of hypoxia 
followed by 24 h of reoxygenation (H/R) in serum-free medium. Control cells were 
simultaneously incubated under normoxic conditions (N). DMOG (1 mM) was applied at 
the onset of reoxygenation (H/R + DMOG). The distribution of vital and apoptotic cells 
was analysed after 24 h by FACS analysis. Data are means ± SD of n=3 separate 
experiments of independent cell preparations. *P< 0.05 vs normoxia (N). 
 
4.2 Effect of DMOG on HIF-1α content during reoxygenation in  
       endothelial cells 
To analyse the effect of hypoxia/reoxygenation, and DMOG during reoxygenation on 
HIF-1α, endothelial cells were incubated under the same experimental conditions as 
described above and HIF-1α protein content was analysed by Western blot analysis.  
Consistent with literature, exposure of endothelial cells to hypoxia induced an increase 
of HIF-1α protein content over time (Fig. 2 A). After 1 h of hypoxia HIF-1α content almost 
reached protein concentrations obtained with 2 h of exposure. Because of these finding 
cells were exposed to 1 h of hypoxia in all further experiments.  
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Next the effect of reoxygenation of HIF-1α content in absence and presence of DMOG 
was analysed. As depicted in Fig. 2 B hypoxia-induced increase of HIF-1α vanished with 
onset of reoxygenation and stayed low for the following 24 h of reoxygenation. However, 
addition of DMOG at the onset of reoxygenation not only maintained HIF-1α content at 
the end-hypoxic level but rather induced a further increase during the reoxygenation 
period, indicating that decrease in HIF-1α is mediated in a PHD dependent manner. A 
similar increase was observed when endothelial cells were exposed to 1 mM of DMOG 
under normoxic conditions. A concentration dependent stabilization of HIF-1α by DMOG 
is depicted in Fig. 2 C showing that 1 mM of the PHD inhibitor led to a maximum 
increase in HIF-1α protein content. Therefore, this concentration was applied in all 
further experiments. 
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Fig. 2 Effect of hypoxia/reoxygenation on HIF-1α protein content in presence and 
absence of DMOG. A) HUVEC were exposed to 0.5, 1, and 2 h of hypoxia while control 
cells were exposed to 2 h of normoxia. Representative Western blot analysis shows HIF-
1α protein content relative to vinculin, taken as internal loading control. B) Cells were 
exposed to 1 h of hypoxia (H, ■) followed by 24 h of reoxygenation (H/R, Δ). 
Dimethyloxalyl glycine (DMOG; 1 mM), a pan-specific inhibitor of prolyl 4-hydroxylases 
(PHD), added at the onset of reoxygenation (H/R+DMOG, ▲) or applied to normoxic 
control cells (N + DMOG, ●). Cells exposed to 1 h normoxia in presence of vehicle, was 
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taken as a control (N, ○). Representative Western blot (upper panel) depicts HIF-1α and 
vinculin, taken as internal loading control. Densitometric analysis of HIF-1α relative to 
vinculin is depicted below. The mean of HIF-1α/vinculin ratio of HUVEC exposed to 1 h 
hypoxia was set to 1. Data are means ± SD of 3 separate experiments with independent 
cell preparations. *P< 0.05 vs H. C) HUVEC were exposed to 1 h of hypoxia followed by 
24 h of reoxygenation. Different concentrations of DMOG 0, 0.1, 0.5, and 1 mM were 
applied at the onset of reoxygenation. Representative Western blot depicts HIF-1α 
protein content relative to vinculin, taken as internal loading control.  
 
 
4.3 Effect of DMOG on p53 protein content during reoxygenation  
Cell cycle arrest and apoptotic cell death are regulated by the tumor suppressor p53 
(Vousden and Lu 2002). Under hypoxia p53 is stabilized and there is evidence that p53 
and HIF-1α interact with each other and influence one another concerning stabilization, 
activation, and proteasomal degradation. In order to analyse whether p53 is involved in 
endothelial cell death and can be influenced by stabilization of HIF-1α, p53 protein 
content was determined by Western blot analysis during reoxygenation in absence and 
presence of 1 mM DMOG. 
As shown in Fig. 3, the protein level of p53 increased in HUVEC exposed to 1 h of 
hypoxia. During reoxygenation, unlike HIF-1α, p53 protein levels maintain throughout 24 
h of reoxygenation. However, in presence of DMOG p53 protein levels declined over 
time.  
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Fig. 3 Effect of DMOG on p53 protein content in HUVEC during reoxygenation in 
comparison to normoxic control cells. Cells were exposed to 1 h of hypoxia (H, □) 
followed by 24 h of reoxygenation (H/R, Δ). DMOG (1 mM) was added at the onset of 
reoxygenation (H/R+DMOG, ▲). Cells exposed to 1 h normoxia in presence of vehicle, 
was taken as a control (N, ○). Representative Western blot (upper panel) depicts p53 
and vinculin, taken as internal loading control. Densitometric analysis of p53 relative to 
vinculin is depicted below. The mean of p53/vinculin ratio of HUVEC exposed to 1 h 
hypoxia was set to 1. Data are means ± SD of 3 separate experiments with independent 
cell preparations. *P< 0.05 vs H. 
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4.4 Effect of PHD2 silencing on HIF-1α and p53 protein content in  
      serum starvation-induced apoptosis during reoxygenation 
To analyse whether the effect of DMOG during reoxygenation on HIF-1α and p53 
content as well as cell survival is due to inhibition of PHD2 by DMOG, a key PHD 
regulating HIF-1α (Berra et al., 2003), PHD2 was silenced by siRNA. Therefore, HUVEC 
were transfected 24 h prior to experiments with siRNA specific for PHD2, while control 
cells were transfected with non-specific siRNA. Afterwards cells were serum starved for 
12 h and exposed to hypoxia and reoxygenation as described above.  
As depicted in Fig. 4 A, PHD2 protein content was significantly reduced in a 
concentration dependent manner by specific siRNA. Here PHD2 silencing also induced 
an increase of HIF-1α and a reduction in p53 protein content as observed before in 
presence of the pharmacologic PHD inhibitor DMOG. Under the same conditions (Fig. 4 
B) apoptotic cells were reduced by 67% in PHD2 silenced cells compared to the 
corresponding cells transfect with non-specific siRNA.  
These data suggest that HIF-1α stabilization and reduction of p53 plays a fundamental 
role for the observed anti-apoptotic effect of PHD inhibition during reoxygenation. 
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Fig. 4 Effect of PHD2 silencing on HIF-1α and p53 protein content and serum starvation-
induced apoptosis during reoxygenation. Cells were transfected with 20 or 50 nM PHD2 
siRNA (PHD2) or 50 nM non-specific control siRNA (NS) 24 h prior to 1 h hypoxia 
followed by 24 h of reoxygenation. A) Representative Western blot depicts PHD2, HIF-
1α, and p53 content relative to vinculin, taken as internal loading control. B) The 
percentage distribution of vital and apoptotic cells determined by FACS analysis are 
given. Data are means ± SD of n=3 separate experiments with independent cell 
preparations. *P< 0.05 vs NS. 
 
 
4.5 Effect of HIF-1α silencing on p53 protein levels and serum  
       starvation-induced apoptosis during reoxygenation 
Pharmacological inhibition as well as silencing of endogenous PHD2 by siRNA led to 
stabilization of HIF-1α and reduction of apoptosis. So the question was raised whether 
HIF-1α is directly involved in endothelial cell survival. To prove its functional role, 
HUVEC were transfected with siRNA specific for HIF-1α, serum starved, and exposed to 
H/R in presence of DMOG as described before. As shown in Fig. 5 A, HIF-1α content 
was significantly reduced in a concentration dependent manner, compared to non-
specific control siRNA transfected cells. Downregulation of HIF-1α was accompanied by 
an increase of p53 content to a similar extend as observed 24 h after hypoxia and 
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reoxygenation (H/R). Analysis of apoptotic cell death (Fig. 5 B) revealed that under this 
condition apoptosis was increased from 40% to 60%.  
 
 
 
 
Fig. 5 Effect of HIF-1α silencing on p53 protein content and serum starvation-induced 
apoptosis during reoxygenation in presence of DMOG. Cells were transfected with 25 or 
50 nM HIF-1α siRNA (HIF-1α) or 50 nM non-specific control siRNA (NS) 24 h prior to 1 h 
hypoxia followed by 24 h of reoxygenation in presence of DMOG (1 mM).  
A) Representative Western blot depicts HIF-1α and p53 relative to vinculin, taken as 
internal loading control. B) The percentage distribution of vital and apoptotic cells 
determined by FACS analysis are given. Data are means ± SD of  n=3 separate 
experiments with independent cell preparations. *P< 0.05 vs NS. 
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4.6 Effect of pharmacological inhibition of p53 on serum starvation- 
      induced apoptosis during reoxygenation 
To analyse whether p53 is responsible for the observed apoptotic cell death, 100 µM 
Pifitrin-α (PFT-α), a specific inhibitor of p53, was applied with onset of reoxygenation 
and apoptotic cell death as well as cell survival was analysed 24 h later. PFT-α caused a 
decrease in apoptosis from 58% to 43% versus cells treated with vehicle only (Fig. 6). 
This indicates that p53 is involved in the observed apoptotic cell death of HUVEC. 
 
 
               
 
Fig. 6 Effect of pharmacological inhibition of p53 during reoxygenation in HUVEC. 
Serum starved cells were exposed to 1 h of hypoxia followed by 24 h of reoxygenation. 
PFT-α (100 µM), a specific inhibitor of p53, was applied at the onset of reoxygenation 
(+). Control cells were treated alike in presence of vehicle (-). The percentage 
distribution of vital and apoptotic cells determined by FACS analysis are given. Data are 
means ± SD of n=3 separate experiments with independent cell preparations. *P< 0.05 
vs control (-). 
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4.7 Effect of DMOG on HIF-1α and p53 localization 
Immunofluorescence staining was performed to determine the abundance and 
subcellular localization of HIF-1α and p53. Apoptosis in endothelial cells caused by 
serum deprivation is characterized by presence of p53 primarily found in the nuclei 
under normoxic conditions (Fig. 7). Exposure to hypoxia induced an increase of p53 
accumulation in cell nuclei accompanied by a concurrent increase of HIF-1α in nuclei. 
During reoxygenation p53 levels were preserved in the nuclei while HIF-1α disappeared. 
In contrast, addition of DMOG at the onset of reoxygenation preserved HIF-1α protein 
levels in the nuclei while p53 vanished below normoxic levels.  
 
 
 
 
Fig. 7 Localization of HIF-1α and p53 in nuclei of HUVEC. Cells were grown on 
coverslips, serum starved for 12 h and exposed to 1 h of hypoxia followed by 24 h of 
reoxygenation (H/R). DMOG (1 mM) was applied at the onset of reoxygenation (H/R + 
DMOG). Control cells were exposed to normoxia only. Endogenous p53 (top row) and 
HIF-1α (bottom row) were both detected with alexa 488-labeled secondary antibody 
(green). Cell nuclei were co-stained with TOPRO-3 (blue). 
 
 
 
 
 
Normoxia Hypoxia H/R H/R + DMOG
HIF-1αHIF-1αHIF-1αHIF-1α 
p53 p53 p53 p53
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4.8 Interaction between HIF-1α and p53 
Earlier reports have shown that HIF-1α can bind to p53. To examine whether HIF-1α 
directly binds to p53 under the experimental conditions described here, co-
immunoprecipitation was performed with anti-p53 antibody. Subsequently, precipitated 
proteins were analysed by Western blot analysis. As shown in Fig. 8, HIF-1α was co-
immunoprecipitated with p53 in apoptotic cells exposed to 1 h of hypoxia (Fig. 8), 
indicating complex formation between both proteins. As expected, after normoxia as well 
as 24 h after H/R no interaction could be detected, since HIF-1α is subjected to rapid 
degradation in presence of O2. On the other hand, no interaction between HIF-1α and 
p53 was observed in presence of DMOG added with onset of reoxygenation. Under this 
condition HIF-1α was preserved while p53 was significantly reduced. Beside p53 the 
heavy light chain of the immunoprecitation antibody (IgG) was detected too. These co-
immunoprecipitation data indicate that during hypoxia HIF-1α/p53 complexes are formed 
while no direct interaction can be observed in presence of DMOG during reoxygenation 
suggesting another mechanism of p53 degradation.  
 
 
            
 
 
Fig. 8 Detection of protein interaction and complex formation between HIF-1α and p53. 
Serum starved HUVEC were either exposed to 1 h of hypoxia (H) or normoxia (N) alone 
or to 1 h hypoxia followed by 24 h of reoxygenation (H/R) in absence or presence of 
DMOG (1 mM) added at the onset of reoxygenation (H/R + DMOG). Equal amounts of 
whole cell lysates were prepared (input) and p53 was immunoprecipitated (IP) with anti-
p53 antibody coupled to protein G-coated magnetic beads. Co-immunoprecipitation of 
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HIF-1α with p53 was analysed by Western blot analysis. The antibody used for 
immunoprecipitation of p53 (IgG) was detected too. 
 
4.9 Effect of PHD inhibition by DMOG on Mdm2 and p53  
The results so far suggest that not the direct interaction between HIF-1α and p53 but 
rather another mechanism might be responsible for DMOG-induced p53 degradation 
during reoxygenation. There is evidence that the ubiquitin ligase Mdm2 is a key 
regulator of p53, capable to inhibit p53 transcriptional activity and to target it for protein 
degradation. 
To elucidate the molecular mechanism by which HIF-1α destabilizes p53, the effect of 
HIF-1α stabilization, p53 and Mdm2 protein content was analysed. As shown in Fig. 9, 
addition of DMOG at the onset of reoxygenation caused a reduction of p53 content, as 
shown before. In contrast, the Mdm2 content increased in a time-dependent manner 
under the same conditions.  
 
 
                            
 
Fig. 9 Effect of DMOG on Mdm2 and p53 protein content. Serum starved HUVEC were 
exposed to 1 h of hypoxia followed by 24 h of reoxygenation in presence of DMOG (1 
mM), applied at the onset of reoxygenation (H/R + DMOG). Samples were analysed 
after 3, 6, 12, and 24 h. Control cells were exposed to 1 h of hypoxia and 24 h of 
reoxygenation only (H/R). Representative Western blot depicts Mdm2 and p53 protein 
content relative to vinculin, taken as an internal loading control.  
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4.10 Interaction between HIF-1α and Mdm2 
To analyse whether DMOG-induced HIF-1α stabilization is responsible for the observed 
Mdm2 accumulation, endogenous HIF-1α was downregulated by siRNA. In comparison 
to cells transfected with non-specific siRNA, HIF-1α silencing abrogated the DMOG-
induced increase in Mdm2 protein content during reoxygenation (Fig. 10 A). In contrast, 
silencing of Mdm2 had no effect on HIF-1α content (Fig. 10 B), suggesting that HIF-1α is 
upstream of Mdm2 expression.  
 
 
 
 
 
Fig. 10 Effect of HIF-1α and Mdm2 silencing on each other. Serum starved HUVEC 
were transfected with 50 nM HIF-1α siRNA (HIF-1α), 50 nM Mdm2 siRNA (Mdm2) or 50 
nM non-specific control siRNA (NS) for 24 h. Afterwards cells were exposed to 1 h 
hypoxia followed by 24 h of reoxygenation in presence of DMOG (1 mM) applied at the 
onset of reoxygenation (H/R + DMOG). As a control, cells were exposed to 1 h of 
hypoxia followed by 24 h of reoxygenation (H/R). Representative Western blots depict 
HIF-1α and Mdm2 content relative to vinculin, taken as a loading control.  
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4.11 Effect of Mdm2 silencing on p53 and analysis of Mdm2 and p53  
        interaction for subsequent p53 degradation 
To prove whether DMOG-induced increase of the ubiquitin ligase Mdm2 during 
reoxygenation is responsible for the observed p53 degradation, Mdm2 was 
downregulated by specific siRNA. Silencing of Mdm2 abrogated DMOG-induced 
reduction of p53 (Fig. 11). In a next step it was analysed whether Mdm2 and p53 interact 
with each other and whether Mdm2 directs p53 to proteasomal degradation. Therefore, 
cytosolic and nuclear protein extracts were prepared and Mdm2 was 
immunoprecipitated. Afterwards immunoprecipitated proteins were analysed by Western 
blot analysis. As seen in Fig. 11 B, Mdm2 was found in both the cytosolic and nuclear 
fraction, whereas p53 was predominantly found in the cytosolic fraction when 
proteasomal degradation was inhibited by the selective and reversible inhibitor MG-132. 
In contrast, p53 was barely detectable in absence of MG-132 or in the nuclear protein 
fraction. These data demonstrate that either silencing of Mdm2 or inhibition of 
proteasomal degradation by MG-132 led to a stabilization of p53, allowing the 
visualization of Mdm2/p53 complex formation and translocation from nucleus to cytosol. 
This indicates that the interaction of both proteins is prerequisite for Mdm2-induced 
translocation and degradation of p53. Taken together, these results show that 
stabilization of HIF-1α by DMOG-induced PHD inhibition elicits Mdm2-mediated 
proteasomal degradation of p53.   
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Fig. 11 A Effect of Mdm2 silencing on p53 during reoxygenation in presence of DMOG. 
HUVEC were transfected with 50 nM Mdm2 siRNA (Mdm2), or 50 nM non-specific 
control siRNA (NS) for 24 h. Afterwards cells were exposed to 1 h hypoxia followed by 
24 h of reoxygenation. DMOG (1 mM) was applied at the onset of reoxygenation (H/R + 
DMOG). As a control, cells were exposed to 1 h of hypoxia followed by 24 h of 
reoxygenation (H/R). Representative Western blot analysis shows Mdm2 and p53 
protein content relative to vinculin, taken as a loading control.  
 
 
                             
 
Fig. 11 B Effect of MG-132, a selective inhibitor of proteasomal degradation, on Mdm2 
and p53, co-immunoprecipitated from cytosolic and nuclear protein fractions. Cells were 
exposed to 1 h of hypoxia followed by 24 h of reoxygenation in presence of DMOG (1 
mM), applied at the onset of reoxygenation (H/R + DMOG). MG-132 (20 µM) was added 
during the last 6 h of reoxygenation (+). Cytosolic and nuclear fractions were prepared 
from equal amounts of cell homogenates and Mdm2 was immunoprecipitated with anti-
Mdm2 antibody coupled to protein A-coated magnetic beads. A representative Western 
blot depicts immunoprecipitated Mdm2 and p53. 
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4.12 Effect of Mdm2 silencing on DMOG-induced cell survival 
To investigate the potential effect of HIF-1α dependent Mdm2 protein accumulation on 
DMOG-induced cell survival, Mdm2 was silenced by siRNA. As described before 
HUVEC were transfected with Mdm2 specific or non-specific siRNA as a control, and 
were serum starved 12 h before experiments. Afterwards cells were exposed to 1 h 
hypoxia followed by 24 h of reoxygenation in presence of DMOG. Control cells were 
treated alike under normoxic conditions. Apoptotic cell death and vital cells were 
determined 24 h after experiments by FACS analysis. As shown in Fig. 12, Mdm2 
silencing abolished the DMOG-mediated reduction of apoptosis. Accordingly, the 
number of vital cells was significantly reduced. This indicates that Mdm2 is required for 
the protection of endothelial cells against apoptotic cell death induced by PHD inhibition. 
 
 
 
Fig. 12 Effect of Mdm2 silencing on DMOG-induced cell survival during reoxygenation. 
Cells were transfected with 50 nM Mdm2 siRNA (Mdm2), 50 nM non-specific control 
siRNA (NS), or were non-treated as a control (C), 24 h prior to 1 h hypoxia and 24 h of 
reoxygenation. DMOG (1 mM) was applied at the onset of reoxygenation (H/R + 
DMOG). As a control, non-treated cells were exposed to 1 h of hypoxia followed by 24 h 
of reoxygenation (H/R). The percentage distribution of vital and apoptotic cells 
determined by FACS analysis are given. Data are means ± SD of n=2 separate 
experiments *P< 0.05 vs NS. 
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5. DISCUSSION 
5.1 Мain findings 
The present study was conducted to elucidate the molecular mechanism by which 
inhibition of PHD leads to protection of endothelial cells against ongoing apoptotic cell 
death during H/R. As a pro-apoptotic challenge endothelial cells were cultured in serum 
free medium for 12 h and subjected to hypoxia for 1 h followed by reoxygenation.  
 
The major findings of the present study are: (1) HIF-1α is up-regulated during hypoxia. 
Its degration during reoxygenation can be prevented by application of PHD inhibitor 
DMOG, targeting HIF prolyl 4-hydroxylases. The same effect is achieved by 
downregulation of the specific PHD2 with siRNA. (2) The increased level of p53 protein 
under hypoxia did not alter during reoxygenation, while addition of DMOG significantly 
reduced p53. (3) DMOG, applied at the onset of reoxygenation, caused a reduction of 
apoptosis. (4) Downregulation of HIF-1α under these conditions aggravated ongoing 
apoptosis. (5) Pharmacological inhibition of p53 reduced apoptosis. (6) Stabilization of 
HIF-1α was accompanied by enhanced Mdm2 expression. (7) The detailed analysis by 
gene silencing displayed that Mdm2 is downstream of HIF-1α. (8) HIF-1α stabilization 
enhanced the binding between p53 and Mdm2 and subsequent degradation of p53. (9) 
Downregulation of Mdm2 by siRNA abolished DMOG-mediated reduction of apoptosis. 
The present study shows that inhibition of PHD at the onset of reperfusion, a maneuver 
called pharmacological postconditioning, reduces ongoing apoptosis in endothelial cells 
during H/R. This anti-apoptotic effect is mediated via HIF-1α and involves Mdm2-
induced degradation of the proapoptotic molecule p53. 
5.2 Inhibition of PHD protects endothelial cells from ongoing  
        apoptosis 
H/R-induced apoptosis of endothelial cells may contribute to tissue injury, organ failure 
and rejection. However, little is known about survival mechanisms capable of 
counteracting endothelial apoptosis. Different strategies aiming at protection of the heart 
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at the onset or during reperfusion have gained much greater interest. Postconditioning, 
introduced by Zhao and coworkers (2003), has now been demonstrated as a novel 
strategy to protect against myocardial ischemia/reperfusion injury. Recently, studies 
proved that the HIF prolyl 4-hydroxylases inhibitor, DMOG significantly increases 
nuclear HIF levels and HIF-1α transcription activity in normoxic microvascular 
endothelium in vitro. Hearts preconditioned by prior DMOG administration exhibited 
significantly reduced infarct size following H/R in rabbits (Ockaili et al., 2005). Another 
study from Natarajan and coworkers (2006) showed that the PHD2 siRNA treatment 
produced significant cardioprotection against H/R stress showed a reduction in infarct 
size by 69% in mouse heart. In this context, HIF-1α has emerged to focus. 
Previous data from our laboratory (Haertel et al., 2010) has shown that transient hypoxia 
protects endothelial cells against apoptosis. Consistent with these previous reports, 
present study confirmes that incubation with DMOG given at the onset of reoxygenation 
resulted in 50% reduction of apoptosis. Therefore, the question whether DMOG 
mediates its effect on apoptosis via stabilization of HIF-1α was analysed. For that 
reason as a pro-apoptotic challenge, endothelial cells were cultured in serum-free 
medium for 12 h and subjected to hypoxia for 1 h followed by reoxygenation. Under 
these conditions, the effect of HIF-1α was examined. Under normoxic conditions, HIF-1α 
protein is rapidly degraded by HIF prolyl 4-hydroxylases. Under hypoxic conditions, 
however, the enzyme fails to hydroxylate HIF-1α due to the low oxygen content. It was 
also found that hypoxia caused a significant increase in HIF-1α content, which was 
undetectable in normoxic control. Inhibition of PDH by DMOG with onset of 
reoxygenation maintains HIF-1α at high level. Downregulation of PHD2 by siRNA 
revealed that HIF-1α can be preserved during reoxygenation. The results indicate that 
HIF-1α stabilization induced by inhibition of PHD leads to reduction of the ongoing 
apoptosis during H/R. However, the question remains, which approach is effective in 
providing protection against apoptosis in endothelial. 
5.3 Inhibition of PHD affects pro-apoptotic p53  
This led to the question about the possible downstream targets participating in induction 
of apoptosis. In previous studies it has been shown that hypoxia is a critical factor for 
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cell death or survival, but the combined effects of hypoxia and reperfusion caused 
pathological consequences that induced endothelial cell apoptosis. An increasing 
number of studies suggest that p53 plays a critical role in hypoxia-induced apoptosis. 
Graeber and coworkers (1996) found that tumor cells containing wild-type p53 were 
more sensitive to hypoxia-induced apoptosis when compared with tumor cells lacking 
functional p53. Long and coworkers (1997) showed the role of p53 in cardiac myocyte 
apoptosis in response to hypoxia. In 1999 Stempien-Otero and coworkers found that 
endogenous p53 protein levels correlated with the initiation of cell death in hypoxic 
HUVEC and showed the elevation of endogenous p53 protein levels via inhibition of the 
proteasome potentiated apoptosis in hypoxic HUVEC. p53 is a transcriptional factor that 
activates a variety of genes involved in DNA repair, cell cycle arrest, and apoptosis. All 
these reports suggest that enhanced stabilization of p53 ultimately leads to apoptosis. 
This raise the question whether p53 is involved in endothelial cell apoptosis. Under short 
hypoxia followed by reoxygenation, an increase in p53 protein levels concomitant with 
endothelial cell death was found. By applying of DMOG at the onset of reoxygenation, 
the level of p53 protein gradually decreased with time and was almost undetectable after 
24 h of reoxygenation. To analyse whether p53 is responsible for the observed 
apoptosis, PFT-α, a p53 specific inhibitor, was applied at the onset of reoxygenation, 
and the amount of surviving cells was analysed 24 h later. Apoptosis was decreased 
from 58% in absence of PFT-α to 43% in presence of PFT-α. This indicates that p53 is 
involved in the ongoing apoptosis. These first findings lead to the assumption that 
stabilizatioin of HIF-1α induces p53 downregulation and the reduction of apoptosis. 
Controversial results have been reported regarding HIF-1α mediated regulation of p53. It 
has been demonstrated in cultured cortical neurons that HIF-1α promotes p53-
dependent apoptosis (Halterman et al., 1999). HIF-1α binds to p53, and the complex 
formation likely plays an important role in the hypoxia-induced stabilization of p53. The 
concept is supported by results from Suzuki and coworkers (2001) showing an 
increased dephosphorylation of HIF-1α, which plays a pivotal role in the stabilization of 
p53 and subsequent activation of the p53-dependent apoptotic pathway during hypoxia. 
An and coworkers (1998), demonstrated that the induction of p53 under severe hypoxia 
is HIF-1α dependent and that it may be achieved by p53 stabilization along with its 
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association with HIF-1α. Results of Ravi and coworkers (2000) indicate that inactivation 
of p53 in tumor cells contributes to activation of the angiogenic switch via amplification of 
normal HIF-1α-dependent responses to hypoxia. To this point, the results left the 
question open whether the effect of p53 is HIF-1α dependent? 
5.4 p53 downregulation is dependent of HIF-1α stabilization 
The data of the present study show that p53 is up-regulated after hypoxia and 
contributes to H/R-induced injury by promoting apoptosis. Because stabilization of HIF-
1α protects endothelial cell from ongoing apoptosis during H/R, it was analysed whether 
endogenous HIF-1α is required for endothelial survival. From these results, it was 
hypothesized that HIF-1α accumulation under pharmacological postconditioning may 
induce downregulation of elevated p53 levels observed during H/R. To show this 
functional role of HIF-1α, gene expression was silenced by using a specific siRNA HIF-
1α following administration of DMOG. Downregulation of HIF-1α increased apoptosis 
from 40% to 60%. This was accompanied by an increase in p53 levels, similar to that 
observed under H/R without silencing of HIF-1α. This assumption is supported by 
reports from Sutton and coworkers (2008) showing that an acute inhibition of p53 
significantly increases HIF-1α expression after H/R renal injury. Additionally, PFT-α 
prevents I/R injury and I/R decrease in HIF-1α expression and has opposing effect to 
those promoted by p53 (Sutton et al., 2008). The balance between the HIF-1α and p53 
responses can determine the outcome of H/R injury. Consequently, when both pathways 
are simultaneously activated under appropriate stress conditions they can counteract 
through complex interactions at various levels. In this context it is of particular relevance- 
that p53 has been shown to directly repress the transcriptional activity of HIF-1α 
(Schmid et al., 2004) by competing with the common coactivator p300. Importantly, 
results from the present study indicate that p53 is a direct target for degradation, what 
suggests that p300 could not be the limiting factor. Further studies on the subject of the 
complex interaction between these two pathways can ultimately determine the degree of 
injury in I/R.  
 
65 
 
5.5 Stabilization of HIF-1α regulates Mdm2, a specific E3-ubiquitin 
       ligase responsible for limiting the levels of p53 
While analysing the mechanism by which HIF-1α modulates p53 response, it was 
observed that addition of DMOG caused degradation of p53 along with HIF-1α 
stabilization, which obviously makes impossible to detect HIF-1α/p53 complex formation. 
The results so far indicate that PHD inhibition virtually exclude a direct interaction 
between HIF-1α/p53. The known roles of Mdm2 in regulating p53 function suggest that 
the effects of hypoxia on Mdm2 and p53 may be interrelated (Lohrum and Vousden, 
1999). Binding to Mdm2 promotes the proteasomal degradation of p53 through Mdm2’s 
action as E3-ubiquitin ligase (Honda et al., 1997). Reduction of Mdm2 expression by 
H/R observed in the experiments could account for corresponding increase in p53 levels 
in endothelium. This is supported by the finding in which the interaction between p53 
and Mdm2 in presence of DMOG, was examined. Immunoprecipitation of both cytosolic 
and nuclear Mdm2 was performed using anti-Mdm2 antibody. Mdm2 was found in both 
cytosol and nucleus, where p53 was almost undetectable. The reduction of p53 content 
was restored when the proteasome inhibitor MG-132 was added. Mdm2/p53 complex 
formation was established in presence of MG-132. Experiments using siRNA directed 
against Mdm2 illustrated a functional role of Mdm2 on p53 accumulation. Silencing of 
Mdm2 abrogated DMOG-induced reduction of p53. These data demonstrate that either 
silencing of Mdm2 or proteasomal inhibition by MG-132 could stabilize p53 by 
abrogating Mdm2-mediated degradation. This indicates that the interaction of both 
proteins is the prerequisite for p53 degradation and is Mdm2 dependent. Taken 
together, these results show that stabilization of HIF-1α by PHD inhibition causes 
Mdm2-mediated proteasomal degradation of p53. This is in line with the evidence 
suggesting that Mdm2 may be involved in the nucleo-cytoplasmic shuttling of p53 that 
translocates from its site of action, as a transcription factor, to its site of proteolysis 
breakdown (Tao and Levine, 1999). Different stress signals produce distinct effects on 
Mdm2 expression. For example, the observed reduction in Mdm2 levels after H/R in 
comparison with hypoxia (data not shown) is consistent with the level during apoptosis. 
In this respect, reduced levels of Mdm2 during H/R are predicted to permit the enhanced 
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nuclear accumulation of p53 that was observed by us in H/R cells. In contrast, the 
application of DMOG leads to accumulation of Mdm2 protein. Therefore, Mdm2 like p53 
appears to be capable of promoting either apoptosis or protection depending on the 
stimulus.  
5.6 HIF-1α induced p53 degradation is mediated via Mdm2  
The results of the present study, together with several other studies (An et al., 1998; 
Koumenis et al., 2001; Ravi et al., 2000), strongly support the role of HIF-1α in the 
regulation of the p53-Mdm2 pathway. Recent studies also indicate that Mdm2 is involved 
in modulating HIF-1α stability under hypoxic conditions (Ravi et al., 2000) further 
supporting the notion that HIF-1α directly interacts with Mdm2 but not with p53. 
Therefore, in context of the study, the question of effect of HIF-1α stabilization on Mdm2 
protein expression and its stability was analysed. Present data show that stabilization of 
HIF-1α led to increased expression levels of Mdm2. To prove whether HIF-1α 
stabilization is responsible for Mdm2 accumulation, the effect of HIF-1α downregulation 
on Mdm2 was determined. Downregulation of HIF-1α abrogated the increase in Mdm2 
level, similarly to that induced by H/R, indicating that HIF-1α stabilization is necessary 
for Mdm2 accumulation. To prove that Mdm2 has no impact on HIF-1α content, Mdm2 
was downregulated by siRNA. Downregulation of Mdm2 did not affect DMOG-induced 
HIF-1α accumulation. These data indicate that Mdm2 is downstream of HIF-1α. Finally, 
the potential effect of Mdm2 accumulation on apoptosis was tested. Downregulation of 
Mdm2 by siRNA showed that DMOG-mediated reduction of apoptosis was abolished. 
The results indicate that Mdm2 is required for the protection against cell death. 
 
In conclusion, results of the present study define a novel mechanism that modulates 
p53 to protect endothelial cells against ongoing apoptotic cell death during H/R. This 
indicates that pharmacological inhibition of PHD by DMOG negatively regulates H/R-
induced expression of p53 by facilitating its degradation most probably via ubiquitination. 
This mechanism is distinct from the proposal that p53 inhibits HIF-1α-mediated 
transactivation by competing for the p300 coactivator (Blagosklonny et al., 1998). Based 
on all these finding, an important role of HIF-1α stabilization in modulating p53-Mdm2 
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system under H/R is illustrated here for the first time. The results demonstrate that 
application of PHD inhibitor given at the onset of reoxygenation, stabilizes HIF-1α, and 
that HIF-1α might act as a novel regulator of p53 by controlling the stability and 
localization of p53 and its regulatory protein Mdm2. The detailed regulatory mechanisms 
of this system need further investigation. Finally, this work indicates that strategies 
targeting PHD activity may provide a useful molecular approach to prevent endothelial 
cells from apoptotic cell death and identifies PHD2 as a new molecular target for 
therapeutic intervention. The approach termed pharmacological postconditioning is a 
more practical solution and could form the basis of much needed and important 
reperfusion strategies. 
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Based on these observations I proposed the model shown in the figure below. 
 
   
 
 
 
Fig. 13 Protective mechanism against ongoing apoptotic cell death during H/R 
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6 SUMMARY  
In the present study a new approach against the ongoing apoptotic cell death during 
hypoxia/reoxygenation (H/R) in endothelial cells was established. Particularly, the 
activation of hypoxia-inducible factor (HIF-1α), plays an essential role in triggering 
cellular protection during hypoxia, but it’s rapidly degradation during reoxygenation, may 
limit its effect on cell survival to the hypoxic period alone. Regulation of HIF-1α 
expression is controlled by repression of oxygen-dependent prolyl 4-hydroxylases (PHD) 
during hypoxia. The present study was conducted to elucidate the molecular mechanism 
by which inhibition of PHD pathway leads to protection of endothelial cells against 
ongoing apoptotic cell death during H/R. The study was performed using an established 
model of cultured monolayers of human umbilical vein endothelial cells to test the 
hypothesis that stabilization of HIF-1α beyond hypoxia exerts anti-apoptotic effects 
during H/R by preventing p53-mediated apoptosis. 
Cells were serum starved for 12 h, then exposed to 1 h of hypoxia (Po2 < 5mmHg) 
followed by 24 h of reoxygenation (Po2=140mmHg). Exposure to hypoxia caused an 
increase in HIF-1α and p53 content. During reoxygenation HIF-1α declined towards 
basal level, while p53 remained unaltered. Under the same conditions, endothelial 
apoptosis was increased to 58% (annexin V staining). Silencing of PHD2, led to an 
increase of the HIF-1α content during hypoxia and maintained it at that level during 
reoxygenation. HIF-1α stabilization was associated by an increase in the Mdm2 content, 
whereas expression of p53 was reduced. PHD2 silencing reduced apoptosis to half. 
Additon of DMOG (1mM, dimethyloxalyl glycine), a PHD inhibitor, at the onset of 
reoxygenation had the same effect. Reduction of p53 content was restored when the 
proteosome inhibitor MG-132 was added. Interaction of Mdm2 and p53 (co-
immunoprecipitation) was increased compared to reoxygenation. Downregulation of HIF-
1α by siRNA increased apoptosis to 60% and abrogated Mdm2-p53 complex formation. 
Downregulation of Mdm2 by siRNA had no effect on HIF-1α but increased p53 level. 
Stabilization of HIF-1α due to PHD inhibition beyond the period of hypoxia defines a 
novel mechanism that exerts anti-apoptotic effects during H/R injury by preventing p53-
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mediated apoptosis and identifies PHD2 as a new molecular target for therapeutic 
intervention. 
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7 ZUSAMMENFASSUNG  
In der vorliegenden Studie wurde eine neue Methode gegen die anhaltende Apoptose 
während der Hypoxie/Reoxygenierung (H/R) in Endothelzellen (EC) etabliert. Die 
Aktivierung des Hypoxie-induzierten Faktors (HIF-1α) spielt eine besondere Rolle in der 
Auslösung zellulärer Schutzmechanismen bei Hypoxie, welcher bei Reoxygenierung 
jedoch schnell zersetzt wird, so dass diese Rolle vermutlich auf die hypoxische Phase 
beschränkt ist. Die HIF-1α-Expression wird durch die Hemmung der 
sauerstoffabhängigen Prolyl 4-Hydroxylasen (PHD) während der Hypoxie reguliert. 
Diese Studie wurde durchgeführt, um den molekularen Mechanismus zu finden, der 
durch die Hemmung des PHD-Weges zum Schutz der EC vor Apoptose nach H/R führt. 
Diese Studie nutzte ein etabliertes Modell in humanen Endothelzellen der 
Nabelschnurvene, um die Hypothese zu testen, ob die Stabilisierung von HIF-1α nach 
der Hypoxiephase anti-apoptotische Effekte während der H/R Schädigung aufzeigt, 
indem die p53-vermittelte Apoptose gehemmt wird.  
Hierfür wurde den Zellen zunächst für 12 Stunden das Serum im Kulturmedium 
entzogen. Anschließend wurden die EC für eine Stunde einer Hypoxie gefolgt von 24 
Stunden Reoxygenierung ausgesetzt. Die Hypoxie verursachte einen Anstieg von HIF-
1α und p53. Während der Reoxygenierung fiel HIF-1α auf niedrige Konzentrationen ab, 
doch die p53 Konzentration blieb unverändert. Unter den gleichen Bedingungen stieg 
die Apoptoserate der EC auf 58% (Annexin V Färbung). Das Ausschalten des PHD2-
Gens führte zu einem Anstieg an HIF-1α während der Hypoxie und gleich hohem HIF-
1α-Gehalt bei der Reoxygenierung. Die Stabilisierung des HIF-1α war assoziiert mit 
einem Anstieg an Mdm2 und einer verringerten Exprimierung von p53. Das Ausschalten 
des PHD2-Gens führte zu einer Halbierung der Apoptoserate. Der Zusatz von DMOG 
(1mM, Dimethyloxalyl glycin), einem PHD Inhibitor, zu Beginn der Reoxygenierung 
zeigte den gleichen Effekt. Die Reduktion des p53 wurde durch den Proteosomen 
inhibitor MG-132 aufgehoben. Die Interaktion zwischen Mdm2 and p53 (Co-
immunopräzipation) war im Vergleich mit der Reoxygenierung erhöht. Downregulation 
von HIF-1α siRNA erhöhte die Apoptoserate auf 60% und hob die Mdm2-p53-
Komplexbildung auf. Downregulation von Mdm2 durch siRNA zeigte keinen Effekt auf 
HIF-1α, erhöhte jedoch die Konzentration an p53. Die Stabilisierung von HIF-1α über die 
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Hypoxiephase hinaus zeigt einen neuen Schutzmechanismus vor einer endothelialen 
H/R-Schädigung auf. Dieser Protektionsmechanismus beruht auf einer Inhibition der 
p53-vermittelten Apoptose und identifiziert PHD2 als ein neues molekulares Ziel für die 
therapeutische Intervention.  
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